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Abstract

IMPAIRED CARDIORESPIRATORY FITNESS FOLLOWING THORACIC
RADIOTHERAPY
Justin McNair Canada, PhD, RCEP

A dissertation submitted in partial fulfillment of the requirements for the degree of Doctor
of Philosophy at Virginia Commonwealth University.

Virginia Commonwealth University, 2018.

Dissertation Adviser: Antonio Abbate, MD, PhD
Department of Internal Medicine, Division of Cardiology

Cancer (CA) is the second leading cause of death in the United States preceded
only by cardiovascular disease (CVD). Over the past 30 years, the 5-year survival rate
for all cancers combined has increased by more than 20%. This improved survival rate
is due to early diagnosis and advances in treatment involving a multimodality treatment
approach that includes radiotherapy [RT] with about half of all CA patients receiving
some type of RT sometime during the course of their treatment. Cardiotoxicity is one of
the most important adverse reactions of RT and leads to a meaningful risk of CVDrelated morbidity and mortality. Radiotherapy-related cardiotoxicity is a heterogeneous
clinical syndrome characterized by symptoms related to impaired cardiac function due

to radiation-injury to one or more cardiac structures. Furthermore, the relative risk of
CVD increases with increasing incidental radiation dose to the heart.
There is not a unified consensus on the definition of CA-related cardiotoxicity
although most trials have focused on changes in resting systolic function, and/or
development of cardiac symptoms. Commonly used tools to assess cardiac function are
insensitive to minor injury hence subtle changes may go unnoticed for many years.
Cardiotoxicity definitions should include a dynamic functional assessment of the CV
system. This may allow detection of latent CV abnormalities before the precipitous
decline of resting myocardial function or the development of CV symptomology that may
impact quality of life.
Cardiopulmonary exercise testing (CPET) including measurement of peak
oxygen consumption (VO2) is the gold standard for the assessment of cardiorespiratory
fitness (CRF). Cardiorespiratory fitness is a strong, independent predictor of mortality,
CVD-related mortality, HF-related morbidity and mortality, CA-related mortality and may
be involved in the pathophysiologic link between anti-CA related treatments and the
increased risk of late CVD events. Emerging evidence indicates CRF may be reduced in
CA survivors and have utility to detect subclinical cardiotoxicity, but this has not been
evaluated in CA survivors treated with RT with significant heart involvement. This
dissertation consists of one literature review and one comprehensive paper that will
examine the ability of CPET to detect subclinical cardiotoxicity.

Chapter 1

Introduction
Cancer (CA) is the second leading cause of death in the United States (U.S.)
with an estimated 1,688,780 new diagnoses expected in the U.S. this year which is the
equivalent of 4,600 new cases each day.(1) Breast CA is the most common CA type in
women involving 252,710 new cases representing 30 percent (%) of all CA in
women.(2) This translates to an annual incidence of new cases of breast CA of 124.9
per 100,000 women per year.(3)
Despite breast CA being the most common type, the most common cause of CArelated deaths are cancers of the lung/bronchus representing 25% and 27% of all
estimated deaths for women and men, respectively.(3) However, over the past 30
years, the 5-year survival rate for all CA combined has increased by more than 20% at
similar rates between both sexes. In fact, the 5-year survival rate of women with breast
CA is now approaching 90%.(2) Currently, there are more than 3.1 million breast CA
survivors in the U.S.(4) The improved survival rate is due to early diagnosis and
advances in treatment of involving a multimodality treatment approach that involves
surgery, systemic therapy (chemotherapy, targeted-therapy, or endocrine therapy [ET]),
and radiotherapy [RT]. The multimodality treatment of CA although shown to improve
CA-specific recurrence and mortality is offset with an increased risk of non-CA related
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morbidity/mortality primarily due to increased cardiovascular disease-related (CVD)
events.(5)
Cardiotoxicity, a general term used to describe "toxicity that affects the heart", is
one of the most important adverse reactions of systemic therapy and RT and leads to a
meaningful risk of CVD-related morbidity and mortality.(6, 7) Cytotoxic agents, targeted
therapies, and incidental exposure of the heart to irradiation can all negatively affect the
CV system and increase CVD risk.(8, 9) This CVD risk is further pronounced in the
setting of combination therapy whereby systemic agents are used in combination or
coupled with RT.(10) The reason is that many of these agents reach targets in the
microenvironment that do not affect only the cancerous tumor. The improving survival of
patients, particularly breast-CA patients (the largest cohort of CA survivors), justifies the
use of this multimodality treatment approach, but strategies must be introduced to
detect, offset and monitor this CVD risk.
The purpose of this review is to describe current anti-CA treatments, identify
those with known cardiotoxic side effects, discuss the proposed mechanisms linking
anti-CA treatments with cardiotoxicity, and review the current detection methods used to
identify cardiotoxicity in the CA patient. This review will primarily focus on the breast CA
patient due to their over-representation for both CA diagnosis and survivorship.
Furthermore, the role of anti-CA treatments on cardiorespiratory fitness (CRF) and its
determinants is discussed highlighting its potential link to cardiotoxicity. Finally, the
measurement of CRF variables using cardiopulmonary exercise testing (CPET) is
reviewed with an emphasis on the potential ability to detect cardiotoxicity in the CA
patient.
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I.

Anti-Cancer Treatments
The American Joint Committee on Cancer (AJCC) has developed a system

based on clinical and pathologic features to classify patients with CA, define prognosis,
and determine the best treatment approaches.(11) This staging system characterizes
patients based on primary tumor (T) size, lymph node (N) involvement, and observance
of metastasis (M) to classify patients based on the extent of disease and the impact of
treatments. Tumor size (T) is graded on a 0–4 scale with higher numbers indicating
larger size and/or invasion into adjacent structures. Node (N) involvement is graded on
a 0-3 scale based upon CA spread to lymph nodes and the number of nodes involved.
Metastasis is classified as 0 (no) or 1 (yes) if the CA has spread to other organs.
Cancers are also staged (0–IV) with higher stages indicating larger tumors or the extent
of spread according to pathological characteristics based upon tumor size and spread to
lymph nodes or other organs. These systems allow application of evidence-based
treatments based on CA subtype and can be used to gauge treatment success with the
goal of a complete response. Complete response is defined as the absence of invasive
carcinoma in the breast and axillary nodes.(11) Specific to breast CA, treatment is also
based on the following clinical and pathological features: menopausal status and patient
age, stage of disease, grade of the primary tumor, hormone status (estrogen receptor
(ER+/-) and progesterone receptor (PR+/-) expression), human epidermal growth factor
type 2 receptor (HER2 +/-) expression, and histologic type.(2)
Surgery is considered standard treatment for early, localized, or operable breast
CA and may include breast-conserving surgery (BCS) referred to as lumpectomy or
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modified radical mastectomy involving removal of the entire breast. In patients with
stages I, II, and T3N1 disease the initial management is surgical resection.(12) Breastconserving surgery coupled with adjuvant RT provides comparable outcomes in terms
of disease-specific survival as compared with mastectomy and confers improved quality
of life thus it is considered the standard of care for early stage breast CA.(13, 14) Breast
conservation therapy (lumpectomy and RT) provides survival equivalent to mastectomy,
preserves cosmetic appearance, while providing a similar low risk of CA recurrence in
the treated breast.(15)
More than 50% of breast CA patients receive RT as part of their treatment.(16)
Radiotherapy can be used alone with curative intent or, more often, is coupled with
surgery and systemic therapy based on tumor characteristics. When used after BCS,
RT reduces the risk of local recurrence (LR) by as much as 70%. A recent metaanalysis of the Early Breast Cancer Trialists Collaborative Group (EBCTCG) in 2011,
including 10,801 women with a median follow-up period of 9.5 years concluded RT
proportionally reduced the rate of LR or distant metastases over the first 10-years by
about half (relative risk = 0.52) and proportionally reduced the rate of breast CA-related
death by approximately one-sixth.(17)
Chemotherapy are systemic agents given as neo-adjuvant therapy (prior to
primary scheduled therapy; i.e. surgery) or as adjuvant therapy (after primary therapy)
consisting of multiple cycles of polychemotherapy to reduce the risk of breast CA
recurrence and provide an additional disease-specific survival benefit.(18)
Chemotherapy used neo-adjuvantly or adjuvantly is used in the treatment of
approximately 38% of all breast CA survivors although is used in the majority of other
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CA types.(3) The most common drugs used for breast CA chemo include
anthracyclines, taxanes, flouropyrimidines (5-fluorouracil), cyclophosphamide, and
carboplatin.(19) However, taxane-based and anthracycline-based regimes have shown
to be superior to cyclophosphamide, 5-fluorouracil, and nonanthracycline-based
regimens.(18) For breast CA patients who warrant chemo, multiple cycles of adjuvant
chemo including taxanes and anthracyclines are considered “gold-standard” and as
such are part of the standard regimen for most patients with node-positive and high-risk
node-negative tumors.(20) This benefit of chemo has also been realized in women with
hormone receptor +/- status regardless of age or menopausal status.(21) However, not
all patients need chemo as the differences in the absolute risk of recurrence is small in
patients with small CA or ER+ CA that also receive adjuvant ET.(22)
Hormone receptor status appears to be an important predictor of derived-benefit
from chemo. The ER is present in about 70% of invasive breast CA and 80% of ductal
carcinoma in situ (DCIS) tumors.(23) Targeted ET with the use of ER modulators or
aromatase inhibitors (AI) in post-menopausal women may reduce LR following BCS and
prevent development of new primary breast CA in the contralateral breast.(24) Tumors
that are ER- benefit substantially from chemo added to ET whereas ER+ tumors do not
glean as much benefit from the addition of chemo on top of ET.(25)
The human epidermal growth factor type-2 receptor (HER2) (found in 20% of
invasive breast CA) historically has been linked to a higher risk of recurrence, relative
resistance to ET due to lower levels of ER expression, and resistance to
cyclophosphamide/methotrexate/5-fluorouracil (CMF)-based chemotherapies.(26)
However, in 2005 the reports of five randomized trials examining the utility of a targeted
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therapy using a humanized monoclonal antibody (Trastuzumab) against the HER2
protein for HER2 overexpressing breast CA demonstrated significant improvements in
disease-free survival (DFS)(50% average risk reduction) and overall survival (OS).(27–
30) This led to the standardization of Trastuzumab as a treatment for HER2+ breast CA.

Chemotherapy
Anthracyclines
Anthracyclines (ACT) are anti-CA compounds derived from Streptomyces
bacteria that are delivered intravenously (IV) and enter cells through passive diffusion.
They bind to proteasomes in the cytoplasm and are then translocated into the cell
nucleus. Proteasomes are predominantly located in the nucleus of neoplastic and
normal proliferative cells. Once ACT enter the nucleus they disassociate from the
proteasome and bind to deoxyribonucleic acid (DNA).(31) In addition, by binding to
proteasomes, ACT inhibit protease activity leading to inhibition of protein degradation,
accumulation of misfolded proteins, and thus induction of apoptosis. The mechanism of
action appears to be multifactorial including cell DNA intercalation, interaction with DNA
binding proteins, induction of apoptosis, formation of reactive oxygen species (ROS),
and anti-angiogenic mechanisms.(32–35) The major drugs used in this class of agents
for breast CA include Doxorubicin (brand names: Adriamycin, Doxil), Epirubicin (brand
name: Ellence), Daunorubicin (brand names: Cerubidine, DaunoXome), and
Mitoxantrone (brand name: Novantrone).(36)
Taxanes
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Taxanes are a class of diterpenes first extracted from the bark of Pacific yew
trees. Taxanes inhibit cell proliferation by blocking mitotic activity through their actions
on microtubules leading to polymerization, mitotic metaphase inhibition, and spindle
microtubule rearrangement.(37) Paclitaxel (brand name: Taxol), Docetaxel (brand
name: Taxotere) are the major taxanes used for the treatment of breast CA.(38) The
Cancer and Leukemia Group B 9344 report was the first to demonstrate the addition of
sequential Paclitaxel therapy improved DFS and OS in comparison to
cyclophosphamide-doxorubicin (AC) chemotherapy.(39) To date, the optimal dosing
regimen appears to be treatment of 4-cycles every 2-weeks in sequential order following
ACT/alkylating agent therapy for reducing breast CA recurrence.(40)
5-Fluorouracil
The fluoropyrimidine, Fluorouracil or 5-fluorouracil (5-FU) works as an
antimetabolite to prevent cell proliferation. It primarily inhibits the enzyme thymidylate
synthase (TS) blocking the thymidine formation required for DNA synthesis.(41)
Fluorouracil (brand name: Adrucil) is a pyrimidine analog that interferes with DNA and
RNA synthesis by mimicking the building blocks necessary for synthesis. It can be used
as a single agent but is most commonly administered via IV in combination with other
chemotherapy regimens.
Cyclophosphamide
Cyclophosphamide is a synthetic alkylating agent chemically related to the
nitrogen mustards with antineoplastic and immunosuppressive activities. It is the most
widely used alkylating agent and has antineoplastic activity in a variety of tumors.(42) In
the liver, cyclophosphamide requires activation by cytochrome P-450 and is then
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converted to the active metabolites aldophosphamide and phosphoramide mustard,
which bind to DNA, thereby inhibiting DNA replication and initiating cell death.
Cyclophosphamide is routinely used in combination with other systemic agents and
usually administered via IV in divided doses relative to bodyweight.

Carboplatin
Cis-diamminecyclobutanedicarboxylate platinum or Carboplatin contains a
platinum atom complexed with two ammonia groups and a cyclobutane-dicarboxyl
residue. It is activated intracellularly to form reactive platinum complexes that bind to
nucleophilic groups such as guanine-cytosine-rich sites in DNA, thereby inducing intrastrand and inter-strand DNA cross-links, as well as DNA-protein cross-links. These
carboplatin-induced DNA and protein effects result in apoptosis and cell growth
inhibition.(43) Carboplatin (brand name: Paraplatin) is usually administered as a rapid
IV infusion over 30-minutes. In HER2+ breast CA, platinum-based agents exhibit a
synergistic cytotoxic effect when coupled with anti-HER2 monoclonal antibodies.(44)

Targeted Therapy
Targeted therapy is the use of agents that target specific changes in CA cell
types whereas chemotherapy agents exert their neoplastic effects irrespective of cell
type. Overexpression of the HER2 receptor protein is present in about one out of five
women with breast CA and is associated with an aggressive subtype that leads to a
poor prognosis. Targeting HER2 expression inhibits epidermal growth factors/ HER2
ligand receptor activity and disrupts the phosphorylation of intracellular tyrosine kinases
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that regulate cell growth and survival. Trastuzumab (brand name: Herceptin) was the
first HER2-targeted therapy approved by the Food and Drug Administration (FDA).(45)
The adjuvant use of Trastuzumab is only known to be effective in tumors with aberrant
expression of HER2 proteins.(46) Initially approved for use in advanced metastatic
breast CA, subsequent studies have demonstrated a reduced risk in CA recurrence
(9.5% decrease) and improved OS (3% improvement) in early-stage breast CA
following surgery.(47) However, all the trials to date showing benefit have utilized
Trastuzumab in combination with varying chemotherapy regimens. Optimal treatment
appears to be for twelve months and can be delivered concurrently or sequentially
following chemotherapy.(20, 28)
Pertuzumab, another humanized monoclonal antibody that targets different
extracellular regions of the HER2 tyrosine kinase receptor and blocks HER2
dimerization is FDA approved in combination with Trastuzumab and Docetaxel for the
treatment of HER2+ metastatic breast CA and for neo-adjuvant use prior to surgery in
HER2+ breast CA. (48)

Endocrine Therapy
Endocrine therapy works in breast CA by inhibiting the effects of estrogen and
progesterone on CA cell growth. They work by inhibiting the body’s ability to produce
hormones or by interfering with the hormones effects on breast CA cells.(49)

Estrogen Receptor Modulators
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Tamoxifen, an estrogen receptor modulator, works by blocking estrogen
stimulation of breast CA cells, inhibiting translocation and nuclear binding of the ER.
This binding inhibits transcriptional activation of estrogen-responsive genes. Tamoxifen
is the only FDA-approved hormonal agent for the prevention of premenopausal breast
CA, treatment of DCIS, and the treatment of post-surgical ER+ breast CA.(50, 51) The
EBCTCG overview on the use of adjuvant Tamoxifen demonstrated administration for
five-years reduced the annual rate of breast CA recurrence by 41% with a 34%
reduction in the annual death rate for women with ER+ breast CA.(51)

Aromatase Inhibitors
Following menopause, the synthesis of ovarian hormones ceases, but estrogen
production continues by conversion of androgens by aromatase. Aromatase is the
enzyme complex involved in the final step of estrogen synthesis by the conversion of
androgens. Aromatase inhibitors (AI) block the actions of aromatase resulting in
estrogen depletion and are used for the treatment of estrogen-responsive breast CA in
postmenopausal women. The American Society of Clinical Oncology (ASCO) guidelines
on adjuvant ET recommend AI treatment in postmenopausal women as either initial
therapy or as adjunctive sequential therapy following Tamoxifen.(52) The addition of AI
in the treatment of postmenopausal ER+ breast CA women results in a modest
improvement in DFS.(53)
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Radiation therapy (radiotherapy)
Radiation therapy is administered to cells either in the form of photons (x-rays
and gamma rays) or particles (protons, neutrons, and electrons). When photons or
particles interact with biological materials, ionization takes place. Ionization is the
process by which an atom or a molecule acquires a negative or positive charge by
gaining or losing electrons to form ions. Ionizations can directly interact with either
subcellular structures or water within the cell generating free-radicals. The direct effect
of radiation is the absorbance of its energy by DNA in chromosomes leading to
ionizations that induce damage including base damage, single-strand breaks, and
double-stranded breaks. Free-radicals generated by radiation interact with other
molecules that possess an unpaired electron and molecules without unpaired electrons
in their outer-shell and can remove a hydrogen molecule from the DNA to cause
damage. Radiation can induce DNA damage at three primary points during the cell
cycle.(12)
Briefly, the cycle of eukaryotic cells can be separated into four discrete phases:
the mitotic (M) phase of the cycle corresponds to mitosis, which is usually followed by
cytokinesis. This phase is followed by the gap 1 (G1) phase, which corresponds to the
interval gap between mitosis and initiation of DNA replication. During G1, the cell is
metabolically active and continuously grows but does not replicate its DNA. The
G1 phase is followed by the synthesis (S) phase, during which DNA replication takes
place. The completion of DNA synthesis is followed by the gap 2 (G2) phase, during
which cell growth continues and proteins are synthesized in preparation for mitosis. The
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cell cycle must progress in a specific order and has checkpoint genes that do not allow
progression to the next event until earlier events are complete.(54)
Radiation-induced DNA damage can occur at the border between G1/ S phase,
intra-S phase, and the border between the G2 phase and mitosis. Cells with intact
checkpoints that have sustained DNA damage become arrested at the next checkpoint
in the cell cycle. The G1/S phase and intra-S phase checkpoints inhibit the replication of
damaged DNA. The G2 phase checkpoint inhibits cells from entering mitosis with
damaged DNA that is transmitted to its progeny.(49)
In addition to its direct effects on DNA, radiation also affects cellular membranes.
Ionizing radiation activates membrane receptor pathways such as epidermal growth
factor (EGFR) and transforming growth factor beta (TGF-) that promote DNA damage
repair and/or cell proliferation.(55)
The goal of RT is to deliver enough ionizing radiation to the tumor site which can
result in absorbed dose. Most patients treated with RT, receive high-energy, external
beam photon therapy. The split-dose repair studies of Elkind et al. have formed the
basis of fractionated radiotherapy wherein a dose is delivered in fractions.(56) When RT
is delivered in fractions as opposed to a single dose it prolongs cell survival or tumor
growth delay. The phase of the cell cycle at the time of RT influences the cell’s inherent
sensitivity to RT. Cells synchronized in late G1/ early S and G2/M phases are most
sensitive, whereas cells in the G1 and mid to late S phases are most resistant to RT. If
cells are given a short time interval between doses, they move from a resistant portion
of the cell cycle to a more sensitive phase enhancing the tumor response to fractionated
RT while this response is somewhat protracted in normal tissue. This concept of re-

19

assortment is also utilized with systemic agents thus making cells more sensitive to
treatment when used in combination with fractionated RT.
External beam photon treatments require high energy (usually 6 to 20 megavolts)
beams with sufficient fluence to penetrate tissue and reach the tumor. To preserve
normal tissue and maximize tumor dose received, beams are arranged to enter the
patient from multiple directions and to intersect at the center of the tumor. Computerized
treatment planning systems using x-ray or computed tomography (CT) to develop
patient-specific anatomic models with beam-specific dose deposition properties to
select beam angles, shapes, and intensities to meet prescribed treatments. Beyond the
ability to define the primary target volume for the tumor these treatment planning
systems allow characterization of the dose administered to normal tissues.(49)
Radiation doses are calculated to maximize tumor control without producing
unacceptable toxicity. The dose of RT required depends on the tumor type, volume of
tumor cells, and the use of RT-modifying agents such as chemo. Dose is quantified in
Gray (Gy) units defined as the absorption of one joule of radiation energy per kilogram
of matter. The effectiveness of a dose of radiation depends on the fraction given with
each treatment as well as the time required to complete the course of RT. Standard
fractionation for RT is defined as 1.8 to 2.25 Gy per fraction per day with a total dose of
whole breast RT of 45 to 54 Gy in the adjuvant setting. A boost or supplementary
irradiation whereby a 10 to 16 Gy boost to the tumor bed region is also commonly used
and provides an additional reduced risk of recurrence in the ipsilateral breast.(57)
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II.

Cardiotoxicity of Anti-Cancer Therapies
There are many recognized adverse cardiovascular (CV) effects of anti-CA

therapies including heart failure (HF), myocardial ischemia/infarction (MI), hypertension
(HTN), thromboembolism (VTE), and arrhythmias.(58) Cardiotoxicity related to anti-CA
treatment is important to recognize as it may have a significant impact on the overall
prognosis and survival of CA patients. Furthermore, it is likely to remain a significant
challenge due to the aging of the population of patients with CA and the introduction of
new CA therapies. The risk of cardiotoxicity needs to be balanced with the benefit of
evidenced-based therapies to eradicate the CA. Early cardiotoxicity can affect a
patient’s ability to complete CA treatments while late toxicity may impact CVD mortality
in the CA survivor.
The National Cancer Institute proposes the use of the Common Terminology
Criteria for Adverse Events to define left-ventricular (LV) dysfunction and HF based on
severity into grades 1 to 5.(59) Grade 1 is defined as asymptomatic with elevations in
cardiac biomarkers or cardiovascular imaging abnormalities, Grades 2-3 include HF
symptoms at mild and moderate exertion. Grade 4 includes severe HF symptoms
requiring hemodynamic support and finally, Grade 5 indicates death. The FDA defines
ACT-induced cardiotoxicity as >20% decrease in left-ventricular ejection fraction (LVEF)
when baseline LVEF is normal and >10% when baseline LVEF is not normal.(60)
There is not a unified consensus on the definition of CA-related cardiotoxicity
although most trials have focused on changes in resting systolic function, namely LVEF
and/or development of HF symptoms.(61, 62) However, systemic therapies and RT are
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known to affect the entire CV system not just resting LVEF. There is a need to expand
the definition of cardiotoxicity to include direct effects on cardiac structure, diastolic
function, conduction abnormalities, vascular function, hemodynamics, coagulability, and
the reserve capacity of the CV system to stress. Cardiotoxicity definitions should include
a dynamic functional assessment of the CV system in addition to measures of resting
myocardial function. This may allow detection of latent CV abnormalities before the
precipitous decline of resting myocardial function or the development of CV
symptomology that may impact quality of life.(63, 64)
Cardiotoxicity risk is potentiated by pre-existing CVD risk factors and
combinations of systemic agents with or without RT.(65) Advanced age, smoking,
sedentarism, obesity, diabetes mellitus, dyslipidemia, HTN, and prior history of CVD are
all associated with heightened risk. The “multiple-hit” hypothesis proposed by Jones and
colleagues infers that at the time of diagnosis breast CA patients already have an
increased risk of developing CVD which is further heightened by the anti-CA
treatment.(66) Cardiotoxicity risk factors associated with CA-related treatments include:
mediastinal RT, systemic cytotoxic agents, ET, and targeted therapies.(65) The next
section of this review will discuss the cardiotoxicity of anti-CA therapies employed in the
treatment of the CA patient.
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Cardiotoxicity due to Chemotherapy
Anthracyclines
Anthracyclines have long been known to cause LV dysfunction and HF with an
incidence in the range of 5-23% of patients.(67) The risk of cardiotoxicity is proportional
to the cumulative ACT exposure(68), however, the CA response rate is proportional to
the increased ACT dose, thus creating a conundrum.(69) Cardiotoxicity from ACT is
heightened when the cumulative dose surpasses 300 milligrams per meter squared
(mg/m2) of body surface area.(70) There is a 5% risk of developing HF with cumulative
doses of 400mg/m2 and increases to >25% at doses of 700 mg/m2. In the U.S., the
combination of polychemotherapy (doxorubicin at 60mg/m2 and cyclophosphamide at
600 mg/m2) in four cycles (total doxorubicin dose at 240 mg/m2) is commonly employed
as treatment for early-stage breast-CA. The risk of symptomatic HF is relatively rare at
this cumulative dose of 240 mg/m2, but asymptomatic CV dysfunction is frequently
observed, and the incidence of late occurring LV systolic dysfunction is not completely
known.(71)
The mechanisms of ACT cardiotoxicity are not completely understood although
the leading hypothesis is that ACTs increase ROS emission within the mitochondria of
cardiac myocytes.(72) In this oxidative stress model of cardiotoxicity, ROS causes
protein/ nucleic acid/ lipid oxidation and leads to cell death/ dysfunction.
Topoisomerase inhibition by ACTs also appears to be important in the
development of cardiotoxicity. Topoisomerases are essential enzymes required for DNA
transcription, replication, or recombination and are expressed in two isoenzymes
(Top2 and Top2) in humans. The Top2 enzyme demonstrates high levels of
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expression in rapidly proliferating cells. The Top2 enzyme is predominantly expressed
in quiescent cells such as myocytes.(73) Inhibition of topoisomerases may be a
beneficial effect of ACTs in high-expression Top2 cells, but may lead to cardiotoxicity
in predominant Top2 cells. Mice with deletion of cardiomyocyte Top2 genes are
protected from doxorubicin-induced cardiotoxity.(74)
Cardiac progenitor cell loss and dysfunction may also be a mechanism of ACT
cardiotoxicity.(75) In an animal model of pediatric mice, exposed to doxorubicin at levels
below acute cardiotoxicity ranges, impaired vascular development with decreased
coronary branching and reduced capillary density upon examination during adulthood
was demonstrated.(76) The adult doxorubicin mice when subjected to myocardial
ischemia developed worse ischemic cardiomyopathy and HF and a reduced ability to
increase capillary density in the infarct border zone. Furthermore, the adult doxorubicin
mice demonstrated increased sensitivity to physical stress from high-volume swimming
with increased cardiac hypertrophy and LV dilatation.(76)
Anthracycline-induced cardiotoxicity can be grouped into 3 categories by its
temporal relationship: acute, early, late. Acute cardiotoxicity occurs during infusion or
within one-week of therapy. The acute cardiotoxicity incidence is low (<1%), can include
pericarditis and arrhythmias, and usually resolves with discontinuation of therapy. Early
cardiotoxicity occurs within 3-12 months of treatment with a peak onset of symptoms of
HF at three-months following completion of therapy. Late cardiotoxicity occurs one to
several years following treatment where patients may be asymptomatic initially and then
develop HF symptoms sometimes even decades after the ACT treatment.(77)
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Taxanes
Arrhythmias are the most common cardiac abnormality observed with the use of
taxanes.(78) Asymptomatic bradycardia is observed in up to 30% of patients taking
Paclitaxel with only 0.1% suffering from serious bradycardias.(78) Taxanes also
interfere with the metabolism and excretion of ACTs and increase the risk ACT
cardiotoxicity particularly at higher cumulative ACT doses.(79) Taxane treatment with
Epirubicin may be less cardiotoxic compared with Doxorubicin.(80) Docetaxel is
associated with an incidence of 2.3-8% for the development of LV dysfunction.(81)

Fluoropyrimidines
Fluorouracil is associated with an incidence of cardiotoxicity ranging from 1%7.6%.(82) The most common manifestations appear to be ischemic in nature including
angina and electrocardiogram (ECG) changes that appear more frequently in those with
underlying CVD.(83) A systematic review of the pathophysiology of 5-FU cardiotoxicity
demonstrated evidence of: interstitial fibrosis, inflammation in the myocardium,
hemorrhagic infarction, endothelial damage, increased myocardial energy metabolism,
depletion of high-energy phosphates, increased superoxide anion levels, reduced
antioxidant capacity, arterial vasoconstriction, alterations in red blood cell (RBC)
structure, and increased platelet aggregation/ fibrin formation.(84) Cardiotoxicity usually
occurs early during treatment and is more common at higher doses and with continuous
infusions.(85)
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Cyclophosphamide
Cyclophosphamide therapy is associated with pericardial effusions, pericarditis,
and HF which occurs in 7-28% of patients.(60) The risk appears to be dose related
(>150 milligram per kilogram [mg/kg]) and usually occurs within 1 to 10 days of the first
dose.(60) Like other systemic agents, additional risk factors include combination with
ACT and/or RT.(86)

Carboplatin
Vascular toxicity is one of the most important late consequences of platinumbased chemotherapy.(87) Cisplatin, another platinum analog is associated with an
accelerated risk of CVD in men with testicular CA.(88) Mechanistically, Cisplatin is
associated with mitochondrial membrane depolarization, ultrastructural abnormalities of
the mitochondria, activation of the endoplasmic reticulum stress response, increased
Caspase-3 activity, and increased apoptosis.(89) Carboplatin, is preferred over Cisplatin
in breast CA due to its lower toxicity profile.(90) To date, platinum-based non-ACT
regimens in clinical trials have not demonstrated a significant signal for the development
of LV dysfunction.(91)

Targeted Therapies – Trastuzumab
The HER2/neu oncogene encodes a transmembrane tyrosine kinase receptor
and shares a very similar structure to the epidermal growth factor receptor. The HER2
gene is involved in embryonic heart development and in the adult, is involved in cardioprotection.(92) The HER2 signaling is involved in growth, survival, and inhibition of
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apoptosis in cardiac myocytes. In situations of biomechanical stress, a ligand growth
factor named neureregulin binds to HER2 to activate the phosphatidylinositide 3-kinase
(PI3K) and mitogen-activated protein kinase (MAPK) cell survival pathways.(93)
Trastuzumab, a humanized monoclonal antibody for the HER2 receptor disrupts
signaling between neureregulin and the HER2 receptor. This may trigger a decline in
myocardial function because of its effects on cardiomyocyte neureregulin-HER2
receptor function. It is believed that exposure to Trastuzumab results in a loss of
contractility due to cellular stunning rather than cardiomyocyte death.(94)
Breast CA patients taking HER2-antagonists also experience increased levels of
norepinephrine with concomitant increases in blood pressure (BP) and heart rate
(HR).(95) Additionally, pre-clinical studies demonstrate beta ()-adrenergic receptor
activity is linked to HER2 expression.(96) Furthermore, trastuzumab triggers
mitochondria oxidative stress and induces the expression and activation of proapoptotic proteins. This causes mitochondrial damage, opening of the mitochondrial
permeability transition pore, and induction of cell death pathways.(97) The incidence of
symptomatic HF with Trastuzumab monotherapy is approximately 4% although can be
as high as 27% with the concurrent use of ACTs.(45) The reduction in LV dysfunction is
considered reversible with the cessation of therapy.(47)

Endocrine Therapy
Tamoxifen use is associated with an overall beneficial effect on lipid profiles,
however long-term clinical trials data have failed to show this translates into a CV
benefit.(98) In fact, the risk of VTE events, and stroke although rare has been shown to
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be increased with the use of tamoxifen over placebo or AI.(99) Anastrozole, an AI with
long-term safety data available has been associated with fewer thromboembolic and/or
cerebrovascular events compared with Tamoxifen, but no significant difference in CV
events.(100)

Radiotherapy
Radiation-induced heart disease (RIHD) is a heterogeneous clinical syndrome
characterized by symptoms related to an impaired cardiac function (diastole and/or
systole) related to radiation-injury to one or more cardiac structures (myocardium,
pericardium, valves, coronary arteries). RIHD may present acutely during treatment in
the form of acute radiation myocarditis, but more commonly develops over the long-term
leading to leading to a restrictive cardiomyopathy.(101) Radiotherapy is associated with
macrovascular, microvascular, endothelial dysfunction, valvular dysfunction,
atherosclerosis, myocardial fibrosis, and pericardial disease.(102)
The damage from RT causes cellular vasodilation, platelet aggregation,
increased vascular permeability, and secretion of adhesion molecules and growth
factors from injured endothelium prompting activation of the acute inflammatory
response. Inflammatory cells secrete pro-fibrotic cytokines which convert fibroblasts to
myofibroblasts that stimulate excessive extra-cellular matrix (ECM) formation, this
accumulation of ECM leads to fibrosis.(103)
In a population-based case-control study of incident HF in female breast CA
patients who underwent contemporary RT, HF with preserved ejection fraction (HFpEF)
defined as a LVEF ≥ 50% with HF symptoms was the most predominant HF
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phenotype.(104) The relative risk of HFpEF increased with increasing mean cardiac
radiation dose (MCRD), and risk of HF was higher in those with prior history of CVD or
atrial arrhythmias.
Late-onset RIHD occurs at a median of 10–15 years after exposure although the
increased risk starts within the first 5 years and persists at least until the 3 rd
decade.(102, 105) The risk of RIHD is magnified by higher dose, delivery technique,
younger age at the start of RT, longer duration since exposure, use of adjuvant
chemotherapy, pre-existing CVD, and pre-existing CVD risk factors.(102) A large metaanalysis involving 289,109 women revealed those who underwent RT for left (L)-sided
vs. right (R)-sided breast CA had a higher risk of CV death and this was more apparent
with prolonged follow-up (≥15 years).(106)
Radiotherapy dose to the heart can vary considerably with mean doses of 1-2 Gy
for R-breast disease, but as much as 10 Gy for treatment of the L-breast.(107) To
account for this variability, a population-based case-control study of women with
invasive breast CA who underwent external-beam RT was undertaken to determine the
risk of CVD considering an individual patient’s RT dose and the presence of CVD risk
factors present during treatment.(105) In women exposed to a range of 0.03 to 27.72
Gy (MCRD = 4.9 Gy) using conventional or modern RT techniques the risk of major CV
events increased linearly with MCRD to the heart. Cardiovascular disease risk
increased 7.4% per Gy of mean heart dose with no discernible threshold dose below
which CV risk did not exist.(105)
The heart dose of RT in the CA patient has decreased over time with the use of
modern RT techniques.(108) This includes the application of 3-dimensional CT
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treatment planning for accurate heart dose and volume calculation, cardiac shielding,
reduced heart dose per fraction (<2.0 Gy/day), reducing total heart dose (<30 Gy),
breath-holding techniques, and the use of intensity-modulated RT.(109)
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III.

Methods to Detect Cardiotoxicity in the Patient with Cancer

Methods to detect cardiotoxicity in the CA patient include multi-modality cardiac
imaging to assess ventricular function, cardiac-specific biomarkers, and exercise testing
while taking into account the patients’ intrinsic CV risk factor profile.(8) Chemotherapyrelated cardiac dysfunction (CTRCD) was first described in the late 1960’s based upon
the presence of HF symptoms following the introduction of ACT for the treatment of
CA.(110) The usefulness of LVEF by non-invasive cardiac imaging to detect
cardiotoxicity was first reported in 1981 and initiated an era of using symptomology and
assessment of LV function to monitor cardiotoxicity in the CA patient.(111) The
evaluation of LVEF has emerged as the most widely used strategy for detecting
changes in cardiac function during CA treatments. Resting LVEF, however, only
provides a snap-shot of cardiac function, is dependent upon preload and HR, and is not
prognostic in patients with preserved LVEF (>50%).(112) Impairments can also occur in
diastolic relaxation and filling following CA therapy despite a preserved LVEF.(113)

Radionuclide Imaging
A multi-gated acquisition (MUGA) scan provides a cinematographic (cine) image
of the beating heart by using a radioactive tracer that emits gamma rays that is injected
into the blood with a gamma camera to detect the radiation released by the heart. It has
historically been used to calculate the LVEF, define clinical cardiotoxicity, and risk
stratify patients undergoing chemotherapy.(114) Guidelines for the use of MUGA to
detect an asymptomatic decline in LVEF were developed to guide ACT treatment using
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an LVEF decrease of ≥10% to indicate cardiotoxicity.(114) The advantages of MUGA
for the assessment of LVEF are its high reproducibility, low variability, few technical
limitations, and its widespread use in clinical practice.(115) It outperforms twodimensional echocardiography (2DE) with respect to accuracy and reproducibility of
LVEF measurements.(116) The primary disadvantage of MUGA is incidental radiation
exposure.(117) Furthermore, MUGA has significant variability in measurements of LV
diastolic function, is non-informative on valvular or pericardial disease, and requires the
use of supine bicycle exercise to measure LV functional reserve which is not readily
available in standard clinical practice.(118)

Echocardiography
Echocardiography (echo) is the cornerstone of cardiac imaging due to its
widespread availability, safety, ease of repeatability, and lack of radiation exposure. It
uses high-frequency ultrasound waves from a transducer to create images of the heart.
In addition to its ability to determine cardiac dimensions, it also allows a comprehensive
assessment of systolic and diastolic function at rest and with exercise, cardiac valves,
the aorta, and the pericardium in the patient.(119)
The most commonly used parameter for estimating LV function with echo is the
LVEF. The recommendations for chamber quantification from the American Society of
Echocardiography and European Association of Echocardiography have established an
LVEF ≥ 55% as normal with a reference range of 53 – 73% using the modified biplane
Simpson’s technique with 2DE.(120, 121) Changes in loading conditions are frequent
during chemotherapy and may affect the LVEF due to volume expansion with IV
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administration or volume contraction due to vomiting or diarrhea. However, the
incorporation of contrast, stress, three-dimensional, speckle-tracking, and tissue
Doppler imaging echocardiography improve its clinical predictive value.
Although LVEF is a strong predictor of cardiac outcomes in the general
population, 2DE often fails to detect small changes in LV systolic function.(122) A study
by Thavendiranathan et al., concluded 2DE to be reliable in the detection of 10%
differences in LVEF in CA patients undergoing chemo.(123) A drop in LVEF of 10% is
highly significant and may be irreversible suggesting more sensitive parameters of LV
function would be useful.(124) This lack of sensitivity has led to the increasing use of
speckle-tracking echo and Doppler imaging to detect subtle changes in myocardial
function.
Speckle tracking or strain-imaging utilizes the movement of the coherent
ultrasound backscatter speckle pattern within echo images to assess myocardial strain
throughout the cardiac cycle. The ventricular myocardium simultaneously shortens
during systole in the longitudinal and circumferential planes and thickens in the radial
plane, with reciprocal changes in diastole. Strain imaging allows for assessment of
myocardial shortening and lengthening throughout the cardiac cycle by assessing
regional myocardial strain and strain rate. Strain is defined as the change in length of a
segment of myocardium relative to its resting length and is expressed as a %; strain
rate is the rate of this deformation. Global longitudinal strain (GLS) is the preferred
marker of myocardial deformation for the early detection of sub-clinical LV
dysfunction.(125)
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In 81 breast CA patients treated with chemo who were followed for 15-months
with quarterly echo, the GLS after the completion of ACT predicted subsequent
CTRCD.(126) Erven et al. demonstrated the ability of strain to detect deficits in breast
CA patients undergoing RT wherein L-sided patients demonstrated strain and strain rate
reductions after RT that was dose dependent with abnormalities in segments exposed
to >3Gy.(127)
Diastolic dysfunction often precedes changes in systolic dysfunction in patients
receiving anti-CA therapies.(128) An early reduction in the mitral annular early diastolic
velocity (e’) has been repeatedly observed in patients receiving ACT chemotherapy and
appears to predict future decline in systolic function.(113)

Cardiac Magnetic Resonance Imaging
Cardiac magnetic resonance imaging (CMR) is very accurate for the calculation
of LV mass, volumes, and LVEF(129) and when coupled with late-gadolinium contrastenhancement (LGE) is considered the gold-standard for the determination of myocardial
tissue structure.(130) The use of CMR may identify a higher prevalence of myocardial
injury/scarring in the CA patient and has higher intra- and inter-observer reproducibility
compared with echocardiography.(131) It also allows characterization of myocardial
edema, inflammation, and fibrosis thus permitting detection of early and late
cardiotoxicity in the CA patient.(132) The benefit of CMR is that it is non-invasive, does
not involve radiation, and demonstrates high-resolution through high contrast to noise
ratios providing enhanced discrimination between endocardial and epicardial
borders.(133) Disadvantages include lack of widespread availability, higher cost, and
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contraindications involving ferromagnetic devices (i.e. pacemakers, defibrillators, breast
tissue expanders) and claustrophobia.(125)
In CMR, the magnetic fields affect the hydrogen nuclei in the body, which act like
miniature magnets. Gradients created by additional coils in the scanner cause a
spatially related difference in how these hydrogen nuclei are affected. Generated
radiofrequency (RF) pulses can then be used to manipulate the hydrogen nuclei in
select planes of any predetermined location and size. Owing to their magnetic
properties, the hydrogen nuclei that are affected by the RF pulse will give off an
electromagnetic signal that can be detected, transformed, and displayed as a 2- or 3dimensional image. Gating of images by HR is achieved by ECG leads placed on the
patient. Cine imaging provides moving images of the heart and surrounding structures.

Cardiac-specific Biomarkers
Cardiotoxicity in the CA survivor defined by LVEF is not sensitive to detect late
declines in heart function and the presence of a normal LVEF does not exclude the
possibility of cardiac dysfunction.(48) Measurement of cardiac biomarkers can be a
valid diagnostic tool for early diagnosis, assessment, and monitoring of cardiotoxicity.
They can be easily repeated, are minimally invasive, allow early diagnosis, are relatively
low cost, and do not predispose to incidental irradiation.(124) There may also be benefit
from combining circulating biomarkers with the results of imaging modalities.(134)
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Markers of Myocardial Injury – Cardiac-specific Troponins
Cardiac troponin (cTn) is the recommended biomarker for acute cardiac injury
and elevations correlate with clinical severity, mortality, and cardiotoxicity from anti-CA
therapies.(135) Cardiac troponin I (cTnI) and troponin T (cTnT) are the cardiac isoforms
of regulatory proteins involved in muscle contraction thus when they are released into
the circulation are highly specific for myocardial damage.(136) These two isoforms arise
from the same circumstances (i.e. cardiac injury), but vary in concentration, and show
differences in diagnostic accuracy.(137) Abnormally elevated levels of circulating cTn
are found in HF patients without obvious myocardial ischemia or the absence of CAD
suggesting ongoing cardiomyocyte injury or necrosis.(138)
Studied most extensively in ACT-induced cardiotoxicity, cTn identifies patients at
risk of future cardiotoxicity, have high negative predictive value to identify those at low
risk of toxicity, and strongly correlate with changes in LVEF.(139, 140) In L-sided breast
CA patients undergoing RT who were chemotherapy-naive, cTnT increased in a
significant proportion of patients (21%) after RT, and correlated with whole heart dose
and LV chamber dose.(141) Recently, highly sensitive cTn assays have been
developed that can measure to an order of magnitude lower than previously
possible.(142) This allows detection of some cTn level in most individuals likely due to
cardiomyocyte turnover and may allow detection of subclinical cardiac dysfunction.(142)

Markers of Left Ventricular Wall Stress - Natriuretic Peptides
Natriuretic peptides are secreted by the heart and produced in response to
ventricular wall stress from pressure or volume overload.(143) The natriuretic peptides,
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B-type natriuretic peptide (BNP) and its amino-terminal fragment precursor N-terminal
pro-brain natriuretic peptide (NTproBNP) are recommended for the diagnosis and risk
stratification of patients with HF although NTproBNP may be more useful to recognize
early subclinical cardiac dysfunction.(144, 145) In the primary care setting involving
patients without HF, NTproBNP levels can also discern between the presence of LV
systolic dysfunction using a cut-off value of 125 picograms per milliliter (pg/mL).(146) It
must be noted however that NTproBNP varies with age, gender, and renal
function.(147)
In CA patients, natriuretic peptides generally correlate with increased risk of
subsequent cardiotoxicity and elevated NTproBNP raises concern for elevated filling
pressures, but professional organizations encourage further study on their utility before
standard recommendations can be made.(125) However, it has been shown that
NTproBNP levels are higher after RT for L-sided breast CA compared with non-RT
matched controls and that NTproBNP correlates with heart volume and %volume of
heart receiving higher doses.(148) It is noteworthy, in this same study cTnI levels did
not significantly change following RT and remained below the cut-off threshold.

Emerging Novel Biomarkers
The American College of Cardiology Foundation/ American Heart Association
guidelines for the management of HF give a Class IIb rating for the measurement of
biomarkers of myocardial injury/stress or fibrosis and identify Galectin-3 for added risk
stratification in the chronic HF patient.(145) Galectin-3, a β-galactoside–binding lectin
member of the galectin family is also a marker of the inflammatory response in HF. Its
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expression is increased in activated macrophages and is involved in pathological
remodeling leading to fibroblast proliferation and collagen deposition.(149)
C-reactive protein (CRP) is an acute phase reactant synthesized by hepatocytes
in response to pro-inflammatory cytokines and is part of the innate immune
response.(150) In addition to being a non-specific marker of an inflammatory process,
CRP plays a key role in the inflammatory process of atherosclerosis.(151) Highsensitivity C-reactive protein (hsCRP) allows detection of subclinical inflammation and is
associated with worsening hemodynamics and outcomes in heart failure.(152) In the
prediction of cardiotoxicity, work has shown correlations between hsCRP levels and
later development of cardiomyopathy in patients treated with targeted therapies (i.e.
Trastuzumab).(153)
Together, these novel biomarkers with HF risk status properties and mechanisms
similar to established anti-CA cardiotoxic mechanisms would seem to be viable
candidates to quantify the incidence of late cardiotoxicity, but to date their utility is
equivocal.(134)

Stress testing
Stress testing can elicit CV and pulmonary abnormalities not present at rest and
allows the quantification of functional reserve through the use of physical stress (i.e.
exercise) or pharmacologic stress (i.e. sympathomimetic agents).(154) Exercise ECG
testing has been used for over 60 years to provoke and identify myocardial ischemia,
but over the last several decades been increasingly applied to assess CV risk.(155)
When coupled with imaging modalities such as echo or perfusion studies it can provide
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even greater diagnostic accuracy.(154) Exercise capacity and assessment of cardiac
contractile reserve are independent predictors beyond coronary anatomy and
LVEF.(156, 157) The potential role of exercise capacity to diagnose CA-related toxicity
is discussed in section IV of this review.
In a study comparing the incidence and distribution of CAD after L-sided versus
R-sided RT following BCS for early-stage breast CA (12-years post-RT), the L-sided
group demonstrated a significantly higher prevalence of stress abnormalities (59% vs.
8%) using stress echo or perfusion studies.(158) Furthermore, the L-sided abnormalities
were predominantly (70%) in the L-anterior descending artery region illuminating the
importance of RT techniques.(158)
Stress echocardiography has shown usefulness in the detection and prognosis of
stable CAD in patients with an intermediate or high pre-test probability for CAD who
underwent chemotherapy regimens associated with ischemia (i.e. 5-FU).(159) Kearney
et al. demonstrated the utility of stress echo using strain to detect subclinical LV
dysfunction in long-term (36 10 years) CA survivors following prior ACT exposure
(118 years post-treatment).(160) Similarly, Khouri et al. showed the superiority of
exercise 2DE to detect subclinical cardiotoxicity not apparent with resting 2DE in breast
CA patients undergoing adjuvant therapy.(161)
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IV.

Cardiorespiratory Fitness in Breast Cancer Patients Who Have
Undergone Anti-Cancer Treatments.

Cardiorespiratory fitness (CRF) is a strong and independent predictor of both allcause and CVD-related mortality wherein high-levels confer protection.(162, 163)
Furthermore, it is a predictor of breast CA-specific mortality as well as the risk of a
breast CA diagnosis.(164, 165) Finally, it appears to be reduced in breast CA
survivors.(166)
Cardiorespiratory fitness is defined as the ability of the circulatory, respiratory,
vascular, and muscular systems to supply oxygen (O2) during sustained physical
activity. It is typically expressed as maximal oxygen uptake (VO2 max) obtained during
progressive maximal dynamic exercise. Maximal VO2 implies the observance of a
plateau in O2 uptake values which is rarely observed in clinical practice thus the term
peak VO2 is often used as a surrogate.(167)
Cytotoxic anti-CA therapies are associated with fatigue, exercise intolerance,
cardiomyopathies, and skeletal muscle myopathies that can occur with active treatment
and persist in the post-treatment period.(168) This can be due to pain, emotional
distress, anemia, weight gain, sedentarism, sleep disturbances, nutritional deficits,
decreased functional status, medication side-effects, and comorbidities.(169)
An analysis by Peel et al. developed normative values for peak VO2 in breast CA
patients.(170) They identified 27 clinical trials involving a total of 1,856 females (mean
age=52 years) directly measuring peak VO2 in the pre- or post-adjuvant setting.
Adjuvant therapy included chemotherapy in 78% (mostly ACT), RT in 56%, and ET in
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33% of patients. The mean peak VO2 prior to adjuvant therapy was 24.6 ml•kg-1•min-1,
whereas the mean peak VO2 post-adjuvant therapy was 22.2 ml•kg-1•min-1. This
equates to a post-adjuvant reduction in VO2 of -2.4 ml•kg-1•min-1or 10% lower. This was
accompanied by a mean post-adjuvant BMI increase of 2.6 kg/m2. Linear metaregression analysis of BMI and age with peak VO2 did not provide evidence of an
association (P>0.05). Compared with reference values the pre-adjuvant VO2 values
were significantly lower (17%) than that of healthy, sedentary women (29.7 ml•kg -1•min1)

or 83% of predicted (%pred.) (P=0.007). In the post-adjuvant setting, pVO2 was 25%

lower (75%pred.) (P<0.001) compared to healthy, sedentary values. For comparison,
the mean VO2 of a typical 50-year-old breast CA patient (22.6 ml•kg-1•min-1) was similar
to the VO2 of a healthy 60-year-old sedentary woman (~22.7 ml•kg-1•min-1).
Jones et al. evaluated VO2 across the entire breast CA treatment continuum and
assessed its significance in metastatic disease.(171) A total of 248 women (mean age
of 55±8 years) underwent CPET. Patients were divided into four cross-sectional
treatment cohorts: 1) pre-adjuvant (n=20), 2) during adjuvant (n=46), 3) post-adjuvant
(mean time=27 months, n=130), 4) during adjuvant-therapy with metastatic disease
(n=52). In the post-adjuvant cohort, RT was part of treatment in 102 (78%) patients. The
mean peak VO2 was 17.8±4.3 ml•kg-1•min-1 (73% pred.). As expected there was a
significant difference between peak VO2 values observed between the different cohorts
with the metastatic disease cohort displaying the lowest peak VO2 values (16.3±3.5
ml•kg-1•min-1). In the metastatic cohort, peak VO2 in absolute values (L•min-1) held
prognostic utility when comparing those <1.09 L•min -1 wherein the adjusted hazard ratio
for death was 0.32 (95%CI, 0.16-0.67; P=0.002) for a peak VO2 >1.09 L•min-1.
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Germane to this review, individuals in the post-adjuvant setting had a mean VO2 of
18.4±4.1 ml•kg-1•min-1 (78% pred.). This was in the setting of a normal LVEF (62%),
normal peak HR (96% pred. max HR), and normal hemoglobin levels (13.5 g/dL).

1) Central Factors associated with CRF
Maximal VO2 is considered the metric that defines the limits of the
cardiopulmonary system. It is defined by the Fick equation as the product of cardiac
output (CO) and arteriovenous oxygen content difference (a-vO2 diff). Cardiac output
(HR x stroke volume (SV)) is regarded as the primary determinant of CRF(172) thus any
sequelae of anti-CA treatment that impacts chronicity, contractility, preload, or afterload
could adversely affect CO and ultimately CRF.
When considering that the primary analysis of cardiotoxicity in patients receiving
anti-CA therapies revolves around the measurement of LV systolic function to diagnose
HF, it is important to recognize more than half of HF patients have HFpEF.(173) Breast
CA survivors also share a number of HFpEF risk factors (female, older age, HTN,
obesity, sedentary lifestyle).(174)
Khouri et al. assessed CRF, as well as CO (using 2DE) at rest and immediate
post-exercise in 57 women with early-stage breast CA (age=51 years; time postchemotherapy=26 months; LVEF=55%) and sex-matched healthy controls. Peak VO2
was 20% lower in the breast CA cohort with no significant difference between groups for
maximal HR. Post-exercise SV and cardiac index were significantly lower although postexercise left-ventricular end-diastolic volume (LVEDV), LVEF, and LVEF reserve were
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not significantly different between groups. Cardiac index reserve was significantly
related to peak VO2.(161)
Koelwyn et al. evaluated LV volumes and ventricular-arterial coupling and
VO2 during cycle exercise, using 2DE, in 30 older BC patients (age= 61 years; time
post-chemotherapy= 6.5±3.6 years, 77% underwent RT; LVEF=60%) and 30 agematched controls. Peak VO2, sub-maximal exercise LVEDV, SV, and effective arterial
elastance were not different between groups. However, sub-maximal exercise LVEF
was significantly lower secondary to decreased end-systolic elastance (an indirect
measure of LV contractility).(175) These studies insinuate a CV limitation in CRF
despite a normal LVEF.

2) Peripheral Factors associated with CRF
The benefit of CRF assessment is that it provides a global assessment of the
components that transport O2 from the atmosphere into the mitochondria termed the O2
cascade. Any therapy that affects components of the Fick equation (CO or a-vO2 diff)
will reduce CRF. Although CO is considered the primary determinant of CRF, anti-CA
therapies are known to cause vasculature injury, pulmonary dysfunction, anemia, and
skeletal muscle dysfunction.(66)
Beckman et al. evaluated the effect of RT on endothelium-dependent
vasodilation in 16 breast CA patients (>3 years post-RT) compared with healthy
controls. Using vascular ultrasonography and flow-mediated (FMD) endotheliumdependent (FMED) and endothelium-independent vasodilation (FMEI) techniques,
FMED vasodilation was significantly impaired in the irradiated axillary arteries compared
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with the contralateral, non-irradiated arteries and also compared with healthy control
arteries. Conversely, the FMEI vasodilation was greater in the irradiated arteries
compared with the contra-lateral arteries and controls.(176)
Conversely, Jones et al. examined brachial artery FMD in 26 HER2+ breast CA
patients (age=48 years; time post-chemo=20 months; 65% underwent RT, LVEF=64%)
and 10 healthy controls. The brachial artery FMD (FMED and FMEI) was not
significantly different between groups (all P>0.1), and not related to peak VO2 (P>0.5)
although pVO2 was significantly inversely related to BNP (R=-0.53,P=0.006).(174)
Koelwyn et al. extended these findings by demonstrating that brachial artery FMD,
carotid-femoral and carotid-radial pulse wave velocity, and carotid compliance were not
significantly different between breast CA and healthy controls.(175) This suggests large
conduit artery endothelial function and arterial stiffness are not impaired in breast CA
patients.
Reactive oxygen species, mitochondrial dysfunction, and inflammatory processes
have been purported in the literature to be involved in chemotherapy-induced skeletal
muscle dysfunction.(177) In an animal model, with adult mice injected with a single dose
of cyclophosphamide, treadmill running time was decreased and mitochondrial function
(maximal ATP production, phosphocreatine to ATP ratio) remained persistently below
baseline following exposure at 6 weeks.(178)
Decreased CRF may also be the result of peripheral muscle weakness as peak
VO2 is related to leg strength in older BC patients.(179) A majority of the O2 consumed
during exercise occurs in the active skeletal muscle thus a decline in peak VO2 in CA
may be due to a reduction in the quantity or quality of skeletal muscle. Villasenor et al.
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showed that sarcopenia is prevalent and an independent predictor of prognosis in older
breast CA.(180) Finally, Toth et al. demonstrated that before or during CA treatment in
19 CA patients (6=breast), muscle fiber cross-sectional area for both slow-twitch myosin
heavy chain (MHC) I and fast-twitch MHC IIA was reduced (~20%) and correlated with
functional capacity.(181)
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V.

Cardiopulmonary Exercise Testing in Cancer Patients Who Have
Undergone Anti-Cancer Treatments.

Cardiopulmonary exercise testing is most extensively used in the CA literature to
determine eligibility for surgery and post-operative prognosis as it applies to lung CA
surgery.(182) Specific to clinical oncology, in 2008 Jones et al. performed a systematic
review of formal CPET for adults with CA.(183) Using the recommendations for CPET
from the American Thoracic Society/American College of Chest Physicians they
attempted to quantify the quality of CPET results in the literature performed on adult CA
patients. Their results suggest the reporting of CPET methods and data do not comply
with national and international quality standards and they provide recommendations to
improve consistency of data reporting and methodology for exercise-oncology
researchers and clinicians caring for the adult oncology patient.
Using relevant terms, they identified 90 citations that met inclusion criteria.
These 90 studies included 5,179 adults and were dichotomized into two groups: 1)
performed CPET solely for quantification of CRF and 2) CPET performed as part of an
intervention study. By and large, most tests were performed on women and assessed
patients with breast or lung CA either during or after treatment.
Peak VO2 was the most commonly reported exercise variable. In regards to effort
performance, 28/90 (31%) reported peak HR and only 11/90 (12%) reported the peak
respiratory exchange ratio. This has major implications if one is trying to determine the
robustness of peak exercise variables or assess the efficacy of an intervention.
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In regards to assessment of the exercise response, 6/90 (7%) reported the
ventilatory threshold, 3/90 (3%) reported the peak O2 pulse, 11/90 (12%) reported
symptoms for test termination, and only 14/90 (16%) reported some metric of
ventilation. These variables provide both prognostic and pertinent information to detect
the physiologic or possibly pathophysiologic limitations to exercise.(167) Furthermore,
they may be sensitive to change resulting from a therapeutic intervention.(184)

47

Conclusions

In conclusion, CA-associated cardiotoxicity is an important concern in the
growing population of survivors mostly consisting of breast CA patients. Multi-modality
treatments are improving outcomes yet this may come at the expense of increased late
CV risk. Current CV detection methods are based mostly on resting measures of LV
systolic function. There is a need to expand this cardio-detection armamentarium to
include measures of functional reserve such as CRF. The literature to date, although
limited, indicates significantly reduced CRF following anti-CA therapies. The data is
stronger for the adverse effects of anti-CA chemotherapeutic regimens, whereas the
effects of RT with heart involvement, a recognized risk factor for CVD, on CRF has not
been systematically examined. Incorporation of CPET into the assessment of patients
who have received radiation to the chest may help understand the short- and long-term
consequences and enhance detection of toxicity related to this form of anti-CA therapy.
Enhanced detection will likely improve the quality of clinical care and provide insight to
the mechanisms contributing to morbidity/mortality in the chest CA patient.
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Chapter 2: Impaired Cardiorespiratory Fitness Following Thoracic Radiotherapy

ABSTRACT
Introduction: The risk of cardiotoxicity is one of the most detrimental adverse reactions
of radiotherapy (RT) and leads to a significantly increased risk of cardiovascular disease
(CVD) mortality and morbidity. RT induces a cardiomyopathy in a dose-dependent
manner that leads to impairment in cardiac diastolic and systolic function. Clinical
presentation of cardiotoxicity after RT is often delayed several years where the cardiac
reserve is severely impaired and patients show signs of heart failure. In animal models
the injury to the heart, however, starts immediately during RT where subtle structural
and functional changes in the heart are evident early after RT. In the current study we
sought to determine whether patients who had received RT to the chest demonstrated
exercise intolerance, a marker of impaired cardiac reserve, due to impaired cardiac
function.
Methods: We enrolled 30 patients 2.0 (0.6-3.8) years after completion of RT to the
chest for the treatment of cancer (CA) with the radiation field involving at least 10% of
heart volume receiving at least 5 Gray (Gy) of radiation. Patients underwent
cardiopulmonary exercise testing, stress echocardiography, cardiac magnetic
resonance imaging, and biomarkers assessment. Exercise intolerance was defined as a
reduction of peak oxygen consumption (VO2) <83% of predicted.
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Results: The overall cohort was predominantly Caucasian (n=20 [67%]), mostly female
(n=18 [60%]) with a median age of 63 (57-67) years. The peak VO2 was 16.9 (14.420.8) mL·kg-1·min-1 or 62% (52-89%) of predicted, reflecting a peak VO2 <90% predicted
in >75% of cases. The mean cardiac radiation dose for the entire cohort was 5.6 (3.717.8) Gy and demonstrated a significant inverse association with peak VO2 (R=-0.380,
P=0.04). Multivariate regression revealed the diastolic functional reserve index (DFRI)
measured as the velocity of the mitral annulus at tissue Doppler (e’) at rest multiplied by
the change in e’ with exercise (e′rest•Δe′exercise - ß=0.765, P<0.01) and N-terminal probrain natriuretic peptide (NTproBNP) serum levels (ß =-0.389, P=0.04) were both
independent predictors of peak VO2.
Conclusions: Patients with CA who received radiation therapy to the chest involving
the heart show a dose-dependent impairment in cardiorespiratory fitness (peak VO2)
associated with a reduced cardiac diastolic reserve (DFRI) and markers of myocardial
strain due to elevated filling pressures (NTproBNP levels).
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INTRODUCTION
Cancer (CA) is the second leading cause of death in the United States (U.S.)
preceded only by cardiovascular disease (CVD).(1) Over the past 30 years, the 5-year
survival rate for all cancers combined has increased by more than 20% at similar rates
between both sexes.(185) This improved survival rate is due to early diagnosis and
advances in treatment involving a multimodality treatment approach that involves
surgery, systemic therapy, and radiotherapy [RT] with about half of all CA patients
receiving some type of RT sometime during the course of their treatment.(4, 185)
Cardiotoxicity, a general term used to describe "toxicity that affects the heart", is
one of the most important adverse reactions of RT and leads to a meaningful risk of
CVD-related morbidity and mortality.(6, 7) The improvement in survival rate means
there are a greater number of CA patients living with the potential adverse effects of
these anti-CA therapies such as RT. Cardiotoxicity related to RT is important to
recognize as it may have a significant impact on the overall prognosis and survival of
CA patients where the CA-related benefits of RT may be offset by an increased risk of
CVD events.
Radiotherapy-related cardiotoxicity is a heterogeneous clinical syndrome
characterized by symptoms related to impaired cardiac function due to radiation-injury
to one or more cardiac structures. Radiotherapy-related cardiotoxicity may present
acutely during treatment in the form of acute radiation myocarditis, which is rare, and
more commonly develops over the long-term leading to a restrictive-type of
cardiomyopathy.(101)
In a population-based case-control study of incident heart failure (HF) in female
breast CA patients (the most common CA subtype) who underwent contemporary RT,
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HF with preserved ejection fraction (HFpEF) defined as a left-ventricular ejection
fraction (LVEF) ≥ 50% with HF symptoms was the most predominant HF
phenotype.(104) Furthermore, the relative risk of HFpEF increases with increasing
mean cardiac radiation dose (MCRD).(104)
There is not a unified consensus on the definition of CA-related cardiotoxicity
although most trials have focused on changes in resting systolic function, namely LVEF
and/or development of HF symptoms.(61, 62) Commonly used tools to assess cardiac
function (i.e. LVEF) are notoriously insensitive to minor injury, and hence subtle
changes may go unnoticed for many years.(122) When considering that cardiotoxicity
revolves around the measurement of LV systolic function to diagnose HF, it is important
to recognize more than half of all HF patients have HFpEF.(173) Based on the
prevalence of HFpEF, a greater need for dynamic functional assessment of the CV
system in addition to measures of resting myocardial function may be warranted in
defining cardiotoxicity. This may allow detection of latent CV abnormalities before the
precipitous decline of resting myocardial function or the development of CV
symptomology that may impact quality of life.(64)
Cardiopulmonary exercise testing (CPET) including measurement of peak
oxygen consumption (VO2) is considered the gold standard for the assessment of
cardiorespiratory fitness (CRF).(186) Cardiorespiratory fitness is a strong, independent
predictor of mortality, CVD-related mortality, HF-related morbidity and mortality, CArelated mortality and may be involved in the pathophysiologic link between anti-CA
related treatments and the increased risk of late CVD morbidity and/or mortality.(66,
163, 164, 187) Emerging evidence indicates CRF may be reduced in CA survivors.(170)
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To date, no one has examined the contribution of contemporary RT on CRF in
patients with CA. Moreover, the degree of reduction in CRF, the primary limitation (i.e.
heart vs. lungs), the determination of a dose-response (MCRD-∆VO2) relationship, and
the mechanistic link attributable to specific anti-CA therapies such as RT are all
unexplored.
The purpose of this pilot project was to evaluate CRF with an emphasis on peak
VO2 and its determinants in a subset of CA patients who had previously undergone RT
involving a significant dose to the heart. The hypothesis of this study is that patients with
CA who have previously undergone RT with radiation dose to the heart have impaired
cardiorespiratory fitness, measured as a reduction in peak oxygen consumption (VO2),
mainly due to abnormal cardiac function, in a dose-dependent manner. The ability to
demonstrate a significant relationship between exercise capacity, cardiac dysfunction,
and RT regimen may signal the importance of CRF assessment in establishing latent
cardiotoxicity.
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METHODS

We designed a single-center pilot prospective study in patients who had
previously undergone irradiation to the chest including a clinically-significant radiation
dose to the heart to obtain a cross-sectional assessment of RT cardiotoxicity.
Potential subjects were identified during their routine clinical visits within the
radiation oncology department at Virginia Commonwealth University (VCU) Medical
Center according to the following inclusion and exclusion criteria:

Inclusion criteria:
•

Previous thoracic radiotherapy to the chest;

•

minimum radiation dose to the heart of at least 5 Gray (Gy) involving at least 10
percent (%) of the heart volume

Exclusion criteria:
•

Inability to provide informed consent;

•

age <18 years;

•

contraindication to magnetic resonance imaging (MRI) with gadolinium contrast use
(including, but not limited to implantable cardioverter defibrillator or pacemaker [not
compatible with MRI] or moderate to severe renal impairment [glomerular filtration
rate <60 mL/min/1.73 m2]);

•

pregnancy or breastfeeding;

•

inability to perform treadmill exercise testing;

•

prior history of significant cardiac disease (including prior myocardial infarction, HF,
myocarditis, pericarditis, left ventricular hypertrophy, cardiomyopathy, pericardial
effusion).
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This study was approved by the VCU institutional review board (HM#20006724)
prior to commencement and all subjects underwent informed consent prior to study
procedures. Clinical data was extracted from the patient medical record. Cancer staging
was based upon the American Joint Committee on Cancer (AJCC) Cancer Staging
Manual 7th edition.(188) Cancers are staged (0–IV) with higher stages indicating larger
tumors or the extent of spread to lymph nodes or other organs.
Radiation dose calculation was performed based on a volumetric computed
tomography (CT) data set obtained during a treatment planning session. A single wellexperienced radiation oncologist performed quantification of total radiation dose and
volume of heart and lung exposed. Using dedicated treatment planning software
(Pinnacle, Koninklijke Philips N.V.), the heart and lungs were manually contoured on
each CT slice generating 3D structures. After radiation beam definition and target dose
calculation, heart and lung dose was determined as maximum, minimum and mean
dose (MCRD, MLRD) to the whole organ volume as well as using dose-volume
histograms to generate %volumes of the heart receiving at least 5 Gy, 10 Gy, 20 Gy, 30
Gy, 40 Gy, and 50 Gy, respectively (Figure 1).
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%Heart volume
receiving at
least 5 Gy

Figure 1. Example of a Dose-Volume Histogram to determine heart exposure during
radiotherapy treatment.
Abbreviations: Gy=Gray units; cGy= centigray.

56

Patients were evaluated for signs of cardiotoxicity through the use of the
following procedures:
•

Cardiopulmonary exercise testing (CPET)

•

Transthoracic Doppler echocardiography at rest and with exercise

•

Cardiac-specific blood-based biomarker analysis

•

Cardiac magnetic resonance (CMR) imaging with delayed-gadolinium enhancement
(LGE).

Additionally, all subjects underwent assessment of anthropometrics, physical activity
participation, and completed a health-related quality of life (HRQOL) questionnaire to
further characterize the cohort.

Cardiopulmonary Exercise Testing
A physician supervised, symptom-limited CPET was administered to all subjects
by a clinical exercise physiologist using a conservative incremental ramping treadmill
protocol wherein the speed and grade increased by approximately 0.3 estimated
metabolic equivalents every 30 seconds.(189) Ventilatory gas-analysis was performed
pre-, during, and post-exercise using a metabolic cart (Parvomedics, Sandy, UT) to
measure ventilation (VE), VO2, and carbon dioxide production (VCO2). Prior to each test,
the O2 and CO2 sensors of the metabolic cart were calibrated using gases of known O2,
nitrogen, and CO2 concentrations and the flow sensor was calibrated using a standard
3-Liter syringe.
Contraindications to testing and test termination criteria were based upon
established American Heart Association/American College of Cardiology guidelines for
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exercise testing.(154) All subjects were instructed to follow standard pre-exercise test
procedures as outlined by the American Thoracic Society/American College of Chest
Physicians and evaluated by a physician prior to testing.(186) This included instructions
to arrive in a fasting state, abstain from smoking at least 8 hours before testing,
continuation of current medications, no exercise the day of testing, and to wear
appropriate exercise attire. Subjects were briefed regarding the exercise protocol and
encouraged to exercise to volitional fatigue. Twelve-lead ECG monitoring was
conducted at baseline, throughout the test, and at least 5-minutes into the recovery
period to assess heart rate (HR) and rhythm. Presence of exercise-induced
atrial/ventricular arrhythmias (atrial fibrillation, ventricular ectopy ≥6/minute) and/or ST-T
wave segment changes (≥1-mm horizontal or downsloping depression) indicative of
myocardial ischemia were considered abnormal consistent with international
guidelines.(154) Peak HR in beats per minute (bpm) was indexed to the age-predicted
maximal HR to give a percentage using the commonly used equation: 220-age.(190)
Chronotropic response to exercise was determined from the chronotropic index (CI),
which is the difference between the peak HR and the resting HR relative to the
metabolic requirement of exercise (peak VO2 minus resting VO2). A CI <0.80 without
beta-blockade and ≤0.62 with beta-blockade was considered indicative of chronotropic
incompetence and considered an abnormal response.(191, 192) Blood pressure was
measured at rest, every two minutes during exercise, and into recovery using an
automated exercise-compatible sphygmomanometer (Tango+, SunTech Medical,
Morrisville, NC).
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During CPET, VE was determined using a pneumotachometer, and expired
gases were sampled to continuously measure VO2 and VCO2. The average value for
VO2 during the last 30 seconds of exercise was used to define peak VO2 expressed in
both absolute values (mL·min-1) and relative to bodyweight (mL·kg-1·min-1). Percent of
predicted normal peak VO2 was calculated according to the prediction equations of
Wasserman and colleagues.(193) The peak respiratory (VCO2/VO2) exchange ratio
(RER) coinciding with the peak VO2 was used to quantify subject effort. Typically, an
RER ≥1.1 is regarded as criterion of an excellent maximal cardiopulmonary effort.(194)
However, in the clinical setting an RER ≥1.1 is often not attained although the
prognostic utility of peak VO2 is retained leading to the acceptance of lower thresholds
of >1.05 as good or ≥1.0 as acceptable effort.(167, 195–197) A RER<1.0 was used to
reflect submaximal effort and/or a non-cardiac reason for stopping in the absence of any
hemodynamic or electrocardiographic abnormalities.(154) A peak VO2 <83% of
predicted values was used to identify an abnormal aerobic exercise capacity or exercise
intolerance.(193)
The peak oxygen pulse (O2 pulse) was defined as the ratio between peak VO2
(mLO2·min-1) and peak HR in units of mL/beat. Percent predicted O2 pulse was defined
as the percentage of the predicted value achieved by dividing the predicted peak VO2
by age-predicted peak HR. An O2 pulse ≤85% of predicted was considered abnormal
based on the findings of Oliviera and colleagues.(198)
The ventilatory anaerobic threshold (VAT) was calculated using the dualmethods criteria wherein the V-slope and the ventilatory equivalents methods were
employed.(199) The V-slope method was graphically determined by departure of the
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VO2 from a line of identity drawn through a plot of VCO2 versus VO2. The ventilatory
equivalents method was determined from graphical and averaged tabular data as the
point wherein a systematic increase in the ventilatory equivalent for oxygen (V E/VO2)
occurs without an increase in the ventilatory equivalent for carbon dioxide
(VE/VCO2).(186) A VAT less than the lower 95% confidence limits for the ratio of
predicted VAT to predicted peak VO2 indicated abnormality.(193)
Ten second averaged VE and VCO2 data, from the initiation of exercise to peak,
were inserted into spreadsheet software (Microsoft Excel, Microsoft Corp., Bellevue,
WA) to calculate the minute ventilation/carbon dioxide production (V E/VCO2) slope via
least squares linear regression. Additionally, the VE/VCO2 slope was indexed to the
peak VO2 to normalize ventilatory efficiency to exercise capacity.(200) The oxygen
uptake efficiency slope (OUES) was determined from the linear relation of V̇O2 versus
the logarithmic transformation of VE during exercise, i.e., V̇O2 = a log10 VE + b, where
‘a’ is the OUES and ‘b’ is the intercept.(201) The %-predicted OUES was calculated by
comparing the observed with the reference values put forth by Sun et al.(202) A %predicted OUES of <89% of predicted was considered indicative of an abnormal CV
limitation as proposed by Barron et al.(203) The oxygen uptake efficiency plateau
(OUEP) was calculated as the 90-second average of the highest consecutive
measurements of VO2 (mL·min-1)/VE (L·min-1) during the exercise period.(202)
A normal CV limitation to exercise was defined as a peak VO2 ≥83% of predicted
values in the setting of an RER ≥1.0 with a peak HR ≥85% of age-predicted maximal
HR.(167, 193, 204) A priori an abnormal cardiovascular response to exercise was
defined as exercise intolerance (peak VO2 <83%) in the presence of any one of the
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following observances in the absence of a pulmonary limitation to exercise and a peak
RER ≥1.0: 1) VAT <95% confidence limits for the ratio of predicted VAT to predicted
peak VO2(193); 2) Chronotropic index (CI) <0.80 or ≤0.62 with beta-blockade(191, 192);
3) OUES <89% of predicted(203); 4) Peak O2 pulse <85% of predicted.(198) This
would indicate subclinical cardiac dysfunction related directly to undergoing RT
treatment and provide a means for early detection of latent heart disease. Inability to
detect an abnormal cardiac limitation to exercise posits that cardiovascular dysfunction
is not what’s driving the exercise intolerance rather it is due to pulmonary limitations,
deconditioning or excess body habitus, or that CPET variables may be insensitive to
detect early cardiovascular dysfunction. A peripheral limitation to exercise was defined
as a peak VO2 <83% with an RER <1.0 in the absence of any cardiovascular or
pulmonary abnormalities.

Pulmonary Function Testing
All subjects underwent standard spirometry prior to exercise including
performance of forced vital capacity (FVC), forced expiratory volume in one second
(FEV1), the mean forced expiratory flow between 25% and 75% of the FVC (FEF25-75%),
peak expiratory flow (PEF), and the directly-measured maximal voluntary ventilation
(MVV) maneuver according to American Thoracic Society standards.(205) The
presence and severity of airflow limitation was assessed according to Global Initiative
for Chronic Obstructive Lung Disease (GOLD) guidelines.(206) Peak exercise VE was
compared to the MVV to assess ventilatory reserve with a peak VE/MVV ratio of >0.80
indicating a pulmonary limitation to exercise.(207) Similarly, forehead pulse oximetry

61

was employed throughout exercise to estimate arterial hemoglobin oxygen saturation.
Oxygen saturation values <95% at rest or >5% decrease with exercise were considered
abnormal and indicative of a pulmonary limitation to exercise.(207)

Doppler Echocardiography
Standard two-dimensional transthoracic echocardiography was performed to
measure left and right ventricular and atrial dimensions, left and right ventricular systolic
function, stroke volume (SV), left-ventricular ejection fraction (LVEF), transmitral flow
velocities [Early (E), Late (A), E/A ratio, and E wave deceleration time (DT)], tissue
Doppler‐derived early diastolic mitral annular velocity (e′), and longitudinal systolic strain
(s′) measured at tissue Doppler averaged between lateral and septal according to the
recommendations of the American Society of Echocardiography.(120, 208, 209) All
echocardiographic measurements and analysis were performed by trained cardiologists.
Doppler derived cardiac output (CO) was estimated by measuring flow across the
left ventricular outflow tract (LVOT) which is determined by the velocity time integral (VTI)
of the Doppler signal directed across the LVOT (LVOT VTI) multiplied by the HR.(210)
The LVOT VTI is used to estimate SV since it reflects the column of blood which moves
through the LVOT during systole, per the following equation: SV = LVOT VTI x Cross
Sectional Area (CSA) of the LVOT.(210) Since estimation of the CSA of the LVOT
represents a potential source of significant error the LVOT VTI alone has been suggested
as a reasonable surrogate for CO measurement.(211)
The E/e’ ratio was calculated as an estimate of LV filling pressures.(212) The e′
velocity was indexed by the DT to obtain a measure (e′/DT) that reflected both the delay
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in relaxation (DT) and the peak velocity in diastolic filling (e′).(213) A higher e′ and shorter
DT would reflect better myocardial relaxation, whereas reduced e′ or prolonged DT would
each reflect impaired relaxation with an additive value.
Stress echocardiography was also performed to assess the LVOT VTI-derived CO
(VTICO), E, lateral e′ and E/e′ ratio at peak exercise by having the patient sit down
immediately post-exercise and obtaining an apical view in < 1-minute. The interval
changes in VTICO, e′ and E/e′ were calculated (ΔVTICOexercise, Δe′exercise, ΔE/e′exercise),
respectively. The diastolic functional reserve index (DFRI) was defined as the product of
e′rest•Δe′exercise.(214)

Cardiac-specific Blood-based Biomarker Assessment
A blood sample was obtained prior to any study procedures and before exercise
to measure the following biomarkers: 1) high-sensitivity cardiac troponin I (hs-cTnI); 2)
high-sensitivity cardiac troponin T (hs-cTnT); 3) N-terminal pro-brain natriuretic peptides
(NTproBNP); 4) galectin-3 (Gal-3); 5) high-sensitivity C-reactive protein (hsCRP). The hscTnI and hs-cTnT plasma samples were collected in K2-Ethylenediaminetetraacetic acid
(EDTA) tubes (Becton, Dickinson and Co., Franklin Lakes, NJ), centrifuged, frozen and
shipped to Hamilton Health Sciences Research Laboratory (Hamilton, ON). The
NTproBNP, Gal-3, and hsCRP plasma samples were collected in K2-EDTA tubes,
centrifuged, and sent to a local laboratory (True Health Diagnostics, Richmond, VA).
The hs-cTnI was determined using the Abbott ARCHITECT (Abbott Laboratories,
Abbott Park, IL) high-sensitivity troponin I immunoassay. The Abbott hs-cTnI assay is a
chemiluminescent microparticle immunoassay for the quantitative determination of the
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cTnI in human plasma and serum. The Abbott hs-cTnI assay reportable range is 1 –
50,000 nanograms per liter (ng/L) with a lower reportable limit of <1 ng/L.(142) The 99th
percentile limit of the distribution of values in a reference population for males = 14.0 ng/L
females = 11.1 ng/L, all-subjects = 13.6 ng/L, and at these concentrations the assay
coefficient of variation (CV) is 5.0%.(142)
The hs-cTnT was determined using the Roche Elecsys Troponin T Gen 5 STAT
(Roche Diagnostics, Indianapolis, IN) electrochemiluminescence immunoassay with an
analytical range from 3 to 10,000 ng/L. The 99 th percentile limit of the distribution of values
in a reference U.S. population is 19 ng/L for both genders, 14 ng/L for females and 22
ng/L for males with a CV of <4%.(215)
The NTproBNP was determined using the Roche Elecsys proBNP (Roche
Diagnostics, Indianapolis, IN) immunoassay for the in vitro quantitative determination of
N‐terminal pro‐brain natriuretic peptide in human serum and plasma. It has a measuring
range of 5.00-35,000 pg/mL with a limit of detection (LOD) of <5.00 pg/mL. The
NTproBNP is a marker of myocardial strain/stretch and a surrogate for HF that has been
found to correlate with radiation dose to the heart in left-sided breast CA patients after
RT(148) and in patients with lung CA.(216) An NTproBNP <125 pg/mL is considered
normal and effectively rules out the presence of LV dysfunction.(146)
Galectin-3 a novel mediator of HF development and progression(145) was
measured with the Abbott ARCHITECT Galectin-3 assay (Abbott Laboratories, Abbott
Park, IL) a chemiluminescent microparticle immunoassay for the quantitative
determination of galectin-3 in human serum and EDTA plasma on the ARCHITECT i
System. Galectin-3 is a galactoside-binding lectin expressed by macrophages during
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phagocytosis and linked to the development of myocardial fibrosis.(217) An elevated Gal3 level (≥17.8 ng/mL) is indicative of increased cardiovascular risk.(218)
High-sensitivity C-reactive protein is the prototypical inflammatory biomarker, and
associated with worsening hemodynamics and outcomes in heart failure.(152) The
hsCRP was determined using an ultrasensitive latex-enhanced immunoassay (Siemens
Healthcare, Elangen, HR).(219) It has an analytical range of 0.175 to 20 mg/L with a CV
of < 10%. A low hsCRP level (<1 mg/L) is associated with a low cardiovascular risk.(220)

Cardiac Magnetic Resonance Imaging
Cardiac Magnetic Resonance imaging was performed on a Siemens Aera 1.5
Tesla scanner (Siemens Healthcare, Elangen, HR) following a clinical assessment,
measurement of renal function, a pregnancy test (if indicated), and completion of an
MRI safety checklist. All studies were interpreted by a single experienced
cardiovascular radiologist. For CMR, selected MRI sequences including cardiac
dimensions (volumes and mass), systolic and diastolic function, and gadoliniumcontrast application was obtained. Cardiac Magnetic Resonance imaging is the goldstandard for the assessment of ventricular function and volumes.(221) Delayed
gadolinium enhancement imaging allows detection of myocardial fibrosis and scar and
provides good diagnostic and prognostic value in cardiovascular diseases.(222) Areas
of late-gadolinium enhancement (LGE) were considered a marker of myocardial injury.
The time-1 (T1) relaxation is a measure in milliseconds of how quickly the net
magnetization vector recovers to its ground state static magnetic field.(223) The
concept of T1 mapping refers to pixelwise illustrations of absolute T1 relaxation times
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on a map. Native T1 values are determined primarily by edema and an increase in
interstitial space and myocardial T1 (native T1 myo) is prolonged in the presence of
extracellular volume (ECV) expansion.(224) In gadolinium-enhanced T1 mapping (postcontrast T1 myo), contrast is distributed throughout the extracellular space and shorten
T1 relaxation times of myocardium proportional to the concentration of contrastagent.(225)
The calculation of the ECV fraction requires measurements of myocardial and
blood T1 before and after contrast administration along with the patient’s hematocrit
value according to the following formula:

Estimation of the ECV fraction was used to quantify diffuse myocardial injury.(226)

Anthropometrics Assessment
Body composition was assessed pre-exercise via body mass index (BMI), waist
and hip circumferences, and single-frequency bioelectrical impedance analysis (BIA)
(Quantum II, RJL Systems, Inc., Clinton Township, MI) by experienced technicians.
Body mass index was utilized to assess weight relative to height and calculated
by the equation: BMI = kg/m2. Overweight was defined as a BMI of 25.0-29.9 kg/m2 and
BMI ≥30.0 kg/m2 as obese.(227) Waist (above the iliac crest) and hip (maximal
circumference of hip/proximal thigh, just below gluteal fold) circumferences were
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obtained to characterize body fat distribution with a flexible tape measure on the skin
surface in duplicate.(204)
Bioelectrical impedance analysis has been validated as a measure of body
adiposity when compared to reference methods such as dual X-ray
absorptiometry.(228) Measurements were obtained prior to exercise in a fasted state
with subjects on their current medications. Resistance and reactance (Xc) was
calculated at a 50-kHz frequency at controlled room temperature with subjects placed in
a supine position with arms and legs abducted approximately 45° to each other. Source
electrodes were placed proximal to the metacarpophalangeal joint on the dorsal
surfaces of the right hand and distal to the transverse arch on the superior surface of
the right foot. Sensor electrodes were placed at the midpoint between the styloid
processes and between the medial and lateral malleolus on the right ankle. Reactance
and Xc were recorded to the nearest ohm and imputed into predictive equations to
calculate fat mass (FM), fat-free mass (FFM), and total body water.(228) Fat mass and
FFM was then indexed to height in meters squared. Percent body fat was calculated
using FM and bodyweight in kilograms.

Quality of Life and Physical Activity Questionnaires
Two questionnaires were used to assess cancer-specific HRQOL
and current levels of physical activity. The Functional Assessment of Cancer Therapy –
General 7-item version (FACT-G7) is a validated HRQOL questionnaire with a scoring
range of 0-28 and a mean value of 18.04  4.97 in healthy individuals wherein higher
scores indicate better HRQOL that can be used with any tumor type.(229)
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The International Physical Activity Questionnaire (IPAQ) – Short form is a
validated instrument to assess physical activity levels in adults.(230) The IPAQ
assesses subjective physical activity participation in the form of walking, moderateintensity, and vigorous-intensity activities weighted by energy requirements defined in
metabolic equivalents (METS) taking into account frequency and duration to provide a
volume of physical activity defined as MET-min/week.(230) Both questionnaires were
administered by trained personnel prior to study procedures.

Statistical Analysis
The objective of this pilot cross-sectional study was to determine the prevalence
of exercise intolerance after chest irradiation, if exercise intolerance was related to
markers of cardiac function, and if the “cardiac dose” – the amount of radiation the heart
is exposed to – correlated with injury or dysfunction.
Being the first study addressing the correlation of cardiac radiation dose with
such parameters, it was not possible to estimate the sample size needed for statistical
purposes. Given the design of this pilot study (single-cohort), the statistical analysis
consisted primarily of descriptive statistics. A sample size of at least 29 subjects was
considered to be required for a correlation coefficient >0.50 to demonstrate a moderate
relationship between variables of interest with a power of 80% (=0.05) while 20
subjects would provide a power of >95% for a correlation coefficient >0.70 (=0.05)
reflecting a strong relationship. Continuous data are reported as median and
interquartile range (IQR) or absolute range for potential deviation from a Gaussian
distribution. Discrete variables are reported as a number and percentage. The
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nonparametric Kruskal-Wallis test was used for comparisons between groups. The Chi
square test was used to compare nominal level variables. Univariate analysis between
CPET variables, cardiac biomarkers, and echo and CMR parameters was performed
using the Spearman rank correlation coefficient test.
Multivariate analysis using a linear regression model was performed using a
stepwise approach including those variables associated with p<0.05 at univariate
analysis from pre-specified cardiac, pulmonary, and body composition parameters to
determine which predictor variables best explain peak VO2. Significant univariate
predictors were assessed for multicollinearity prior to placement in the multivariate
model. An additional correction for type of CA and for use of anthracyclines was
performed by a mixed model of multivariate analysis using a General Linear Model.
Statistical analysis was performed using SPSS version 24.0 (IBM Corp, Armonk, NY).
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RESULTS
Thirty subjects were enrolled between August 2016 - November 2017. During
this time period 106 potential subjects were screened for study inclusion of which 76
were not enrolled for the following reasons:
1) 37 (35%) did not meet protocol minimum RT heart dose requirement;
2) 27 (25%) were not interested;
3) 5 (5%) failed to show up for their appointment;
4) 5 (5%) had contraindications to undergo MRI;
5) 2 (2%) had contraindication to undergo CPET.
Table 1 describes the clinical characteristics of the enrolled subjects which
included 15 (50%) subjects who received RT for lung CA, 10 (33%) for breast CA, 2
(7%) for esophageal CA, 1 (3%) for Hodgkin’s lymphoma, 1 (3%) for a desmoid tumor,
and 1 (3%) for Castleman’s disease. The overall cohort was predominantly Caucasian
(n=20 [67%]), mostly female (n=18 [60%]) with a median age of 63 (57-67) years. The
median time since CA diagnosis was 2.6 years with a total range of 0.3 - 29.0 years.
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Table 1: Clinical Characteristics of the Cohort.
Variable
Cancer type
Lung
Breast
Esophageal
Hodgkin’s Lymphoma
Other diseases
Desmoid Tumor
Castleman’s Disease
Caucasian
Female
Age (years)
Time since Cancer Diagnosis (years)
Time since completion of Chemotherapy (years)
Prior chemotherapy
Anthracycline-based chemotherapy
Time since completion of Radiotherapy (years)

Entire Cohort (N=30)
15 (50%)
10 (33%)
2 (7%)
1 (3%)
1 (3%)
1 (3%)
20 (67%)
18 (60%)
63 (57-67)
2.6 (0.3-29.0)*
1.7 (0-21.8)*
26 (87%)
7 (24%)
2.0 (0.1-28.7)*

Date are listed as median and (interquartile range), or total range*, or n (%).

Non-small cell carcinoma was the primary lung CA type (13/15 [87%]) with the
remaining 2 having small-cell carcinoma. The breast CA cohort (n=10) consisted of
seven (70%) with left-sided disease and three (30%) with right-sided disease. Invasive
ductal carcinoma was overwhelmingly the most common breast CA type (n=9/10 or
90%) followed by one patient with an invasive lobular carcinoma. The prevalence of
hormone receptor and HER2 status of the breast CA cohort was as follows: ER+ = 8/10
(80%), PR+ = 7/10 (70%), HER2+ = 2/10 (20%). Table 2 provides a detailed breakdown
of CA stage by diagnosis (breast CA or lung CA and other diseases).
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Table 2: Cancer Stage of Study Participants.
Stage
Breast CA
Lung CA or other
n=10
diseases
n=20
IA
1 (10%)
1 (5%)
IB
1 (10%)
II
1 (10%)
IIA
1 (5%)
IIB
1 (10%)
1 (5%)
IIIA
3 (30%)
10 (50%)
IIIB
2 (20%)
4 (20%)
IIIC
1 (10%)
Unknown
3 (15%)

Fifteen (50%) of all patients (breast CA =10 (100%), lung CA or other diseases =
5 (25%) had previously undergone surgery. Twenty-six (87%) of all patients (breast CA
= 9 (90%), lung CA or other diseases = 17 (85%) had previously undergone neoadjuvant, adjuvant, or concurrent chemotherapy. Specifically, seven (70%) of the breast
CA patients underwent neo-adjuvant chemotherapy, and 2 (20%) underwent adjuvant
chemotherapy. Twelve (60%) of the lung CA or other disease patients underwent
concurrent chemoradiation followed by 3 (15%) who underwent adjuvant chemotherapy,
and 2 (10%) who underwent neo-adjuvant chemotherapy. Seven (24%) of the total
cohort underwent regimens including anthracyclines which included 6/7 breast CA
patients and one patient with Hodgkin’s lymphoma. Table 3 lists the types of
chemotherapy, frequency of use, and average doses of the cohort. Seven (70%) of the
breast CA patients were on concomitant hormonal therapy at the time of evaluation.
Time since completion of chemo was 1.7 years with a total range of 0.1-28.7 years.
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Table 3: Chemotherapy Regimens of the Cohort.
Chemotherapy Type
n (%)
Taxol
18 (60%)
Carboplatin
13 (43%)
Cyclophosphamide
8 (27%)
Doxorubicin
7 (23%)
Cisplatin
5 (17%)
Etoposide
4 (13%)
Pemetrexed
2 (7%)
Imatinib
1 (3%)
Rituximab
1 (3%)
Nivolumab
1 (3%)
Trastuzumab
1 (3%)
Pertuzumab
1 (3%)
Vinblastine
1 (3%)
Dacarbazine
1 (3%)
Bleomycin
1 (3%)

Dose
483  289 mg/m2
863  636 mg
2540  523 mg/m2
234  44 mg/m2
271  82 mg
597  248 mg/m2
1500  707 mg/m2
300 mg
375 mg/m2 every 3-months
2240 mg
104 mg/kg
1260 mg/kg
36 mg/m2
2250 mg/m2
60 u/m2

Data are listed as n (%) and mean  standard deviation.
Abbreviations: mg/m2=milligrams per meter squared.

All patients had previously undergone neo-adjuvant/adjuvant or concurrent RT
with a median duration of 2.0 years with an absolute range of 0.1 - 28.7 years since end
of RT treatment. Seventeen (85%) of the lung CA and other diseases group underwent
primary RT, 2 (10%) underwent adjuvant RT followed by 1 (5%) who underwent neoadjuvant RT. The median number of RT fractions was 30 (range = 4-35) with a median
of 2.0 (range = 1.5-12.0) Gy per fraction for a prescribed RT dose of 60.0 (range = 30.470.0) Gy. Five of these subjects also had additional previous RT treatments (#fractions
= 4 [range = 4-20], Gy per fraction = 12.0 [range = 1.8-12.0] Gy, total prescribed dose =
48.0 [range = 32.0-60.0]) Gy.
The median number of RT fractions for the breast CA subjects was 32 (range =
16-33) with a median of 2.0 (range = 1.8-2.7) Gy per fraction for a prescribed RT dose
of 60.2 (range = 42.6-66.0) Gy. One of the breast CA patients also had additional
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previous RT treatments (#fractions = 28, Gy per fraction = 1.8 Gy, total prescribed dose
= 50.4 Gy).
The MCRD and MLRD, reflective of the dose contributions from all RT treatments
for each patient, for the entire cohort was 5.6 (3.7-17.8) and 9.4 (6.4-14.5) Gy,
respectively. Specific to CA type, the MCRD for the lung CA and other diseases was
12.4 (range = 3.1-42.0) Gy and the MLRD was 12.7 (range = 3.3-21.5) Gy. The MCRD
for breast CA patients was 3.7 (range = 1.9-5.5) Gy while the MLRD was 6.9 (range =
0.5-14.7) Gy, respectively. Table 4 lists the MCRD, MLRD, mean %heart and lung
volumes that received at least 5 Gy, 10 Gy, 20 Gy, 30 Gy, 40 Gy, and 50 Gy,
respectively. When separating the CA types (breast vs. lung CA and other diseases)
there was a significant difference in MCRD, and the %heart volume receiving at least 5
Gy, 10 Gy, 20 Gy, 30 Gy, 40 Gy, and 50 Gy (all P’s≤0.02) with the lung Ca and other
diseases subjects receiving higher heart doses than breast CA patients.
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Table 4: Heart & Lung Radiotherapy Volumes.
Entire Cohort
Breast CA
N=30
n=10

Heart Volumes
MCRD
V5 Gy
V10 Gy
V20 Gy
V30 Gy
V40 Gy
V50 Gy
Lung Volumes
MLRD
V5 Gy
V10 Gy
V20 Gy
V30 Gy
V40 Gy
V50 Gy

Lung Ca and
Other Diseases
n=20

P-value

5.6 (3.7-17.8)
39.5 (15.8-80.5)
19.3 (8.8-67.3)
7.0 (1.2-35.0)
2.5 (0-15.0)
1.0 (0-7.8)
0 (0-3.0)

3.7 (2.8-4.3)
13.5 (11.5-30.0)
8.2 (2.8-9.0)
1.6 (0.8-3.5)
0.1 (0-2.3)
0 (0-1.0)
0 (0-0)

12.4 (5.5-24.9)
62.0 (36.5-87.2)
40.0 (18.0-73.8)
24.0 (7.0-60.3)
5.1 (0.1-26.5)
2.5 (0-12.8)
0.5 (0-5.5)

<0.001
<0.001
<0.001
<0.01
0.02
0.01
<0.01

9.4 (6.4-14.5)
42.0 (25.7-60.0)
28.7 (20.0-36.8)
17.0 (11.3-25.8)
11.9 (5.5-18.0)
7.0 (3.0-11.0)
2.0 (1.0-6.8)

6.9 (5.7-10.4)
27.4 (17.0-39.7)
20.5 (13.3-29.9)
13.6 (11.3-20.1)
9.8 (7.0-13.5)
5.7 (3.5-9.0)
1.2 (0-2.0)

12.7 (7.6-16.6)
54.0 (29.0-66.5)
33.0 (23.5-43.5)
18.5 (10.8-26.5)
13.0 (4.0-18.5)
10.0 (2.8-14.0)
4.0 (1.0-9.5)

0.06
0.01
0.02
0.28
0.53
0.46
0.03

Values are listed as median and (interquartile range).
Abbreviations: MCRD=mean cardiac radiation dose; V=percent volume of the heart; Gy=Gray
units; MLRD=mean lung radiation dose.

Cardiovascular Risk and Comorbidity Status
Hypertension was the primary established CVD risk factor (n=17 [57%]) followed
by hypercholesterolemia. Table 5 lists the prevalence of CVD risk factors and
cardiovascular medication use amongst the group. Lung disease was the most common
non-CVD-related comorbidity present in 17 (57%) individuals. All subjects were Eastern
Cooperative Oncology Group (ECOG) status 0-1 with a mean Karnofsky grade of
9010.
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Table 5: Prevalence of Established Cardiovascular Disease Risk Factors and
Cardiovascular Medication Usage.
Cardiovascular Disease Risk Factors
N (%)
Hypertension
17 (57%)
Diabetes Mellitus-Type II
7 (23%)
Hypercholesterolemia
14 (47%)
Early Family History of Cardiovascular Disease
9 (30%)
Current Smoker
6 (20%)
Obesity (Body Mass Index > 30)
10 (33%)
Sedentary Lifestyle
12 (40%)
Cardiovascular Medications
Beta-blockers
5 (17%)
Angiotensin blockers
6 (20%)
Aldosterone inhibitors
2 (7%)
Statins
10 (33%)
Calcium channel blockers
5 (17%)
Diuretics
12 (40%)
Thiazide diuretics
7/12 (58%)
Loop diuretics
5/12 (42%)
Anti-platelets
13 (43%)

Anthropometrics Assessment
Nineteen (63%) subjects met BMI criteria for overweight (9 [30%]) or obesity (10
[33%]). Anthropometrics of the group are detailed in Table 6.
Table 6: Anthropometrics of the Cohort.
Variable
Weight (kg)
Body Mass Index (kg/m2)
Waist Circumference (cm)
Waist/Hip Ratio
Fat Mass %
Fat Mass (kg)
Fat Mass Index
Fat-Free Mass %
Fat-Free Mass (kg)
Fat-Free Mass Index

Entire Cohort (N=30)
76.1 (62.2-85.2)
27.1 (23.6-30.6)
96 (84-106)
0.86 (0.83-0.95)
33 (23-40)
23.1 (15.3-33.1)
8.7 (5.3-12.1)
66 (60-77)
51.0 (44.2-60.1)
18.4 (16.6-20.2)

Data are listed as median and (interquartile range).
Abbreviations: kg=kilograms; kg/m 2=kilograms per meter squared; cm=centimeters.
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Cardiopulmonary Exercise Testing (CPET)
The peak VO2 for the entire cohort was 1376 (1057-1552) mL·min-1, normalized
to bodyweight was 16.9 (14.4-20.8) mL·kg-1·min-1 or moderately reduced at 62 (52-89)
% of predicted values based upon age/gender/anthropometrics-based normative
values. Table 7 provides a comprehensive summary of the CPET variables analyzed
with this study. As expected peak VO2 was inversely correlated with age (R=-0.401,
P=0.031). Peak VO2 was not significantly different with regards to gender (P=0.116) or
race (P=0.556). However, it was significantly higher (P=0.008) in the breast CA cohort
compared with the lung CA and other diseases (21.0 [17.8-23.6] mL·kg-1·min-1 versus
16.0 [13.0-18.6] mL·kg-1·min-1) or 93 (77-98) %predicted versus 54 (48-68) %predicted.
Peak VO2 was not significantly different when comparing those who underwent
chemotherapy of any type (P=0.66) versus those who did not undergo chemotherapy.
Peak VO2 was significantly higher (P=0.021) in those who underwent ACT regimens
(22.0 [16.2-23.2] versus 16.6 [14.4-19.6] mL·kg-1·min-1) although it did not correlate with
anthracycline dose when treated as a continuous variable (R=0.535, P>0.2).
The median peak RER was 1.02 (0.95-1.09) with 16/30 (53%) achieving an RER
≥ 1.0, 12/30 (40%) reaching an RER ≥ 1.05, and 12/30 (40%) reaching an RER ≥ 1.10,
respectively. The primary reason for test termination was dyspnea (43%) followed by
fatigue (30%) with 27% stopping for other reasons (musculoskeletal limitations,
lightheaded/dizziness).
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Table 7: Cardiopulmonary Exercise Test Variables.
CPET Variables
Absolute Peak VO2 (mL·min-1)
Percent-predicted Absolute Peak VO2 (%)
Relative VO2 (mL·kg-1·min-1)
Percent-predicted Relative VO2 (%)
Relative Peak VO2 <83% predicted
METS
Oxygen Pulse (mL/beat)
Percent-predicted Oxygen Pulse (%)
Oxygen Pulse <85% predicted
Ventilatory Anaerobic Threshold (mL·min-1)
Percent-predicted VAT (%)
Ventilatory Anaerobic Threshold (mL·kg-1·min-1)
Percent-predicted VAT (%)
VE/VCO2 Slope
VE/VCO2/VO2 ratio
OUES
OUEP
Peak RER
Exercise Time (minutes)
Resting Heart Rate (bpm)
Maximal Heart Rate (bpm)
Percent-predicted APMHR (%)
Chronotropic Index
Heart Rate Recovery-1 (bpm)
Resting Systolic BP (mmHg)
Resting Diastolic BP (mmHg)
Max Systolic BP (mmHg)
Max Diastolic BP (mmHg)
Rate-Pressure Product (Systolic mmHg x HR)
Resting SPO2 (%)
Exercise SPO2 (%)
 SPO2 exercise
VE/MVV ratio
Breathing reserve (Liters)
Peak Minute Ventilation (L·min-1)
Peak Respiratory Rate (breaths·min-1)
Peak Tidal Volume (Liters)

Entire Cohort
1376 (1057-1552)
62 (51-98)
16.9 (14.4-20.8)
62 (52-89)
22 (73%)
4.8 (4.1-5.9)
9.2 (7.5-10.7)
82 (66-96)
13 (45%)
1040 (842-1234)
53 (44-70)
13.5 (11.4-14.7)
54 (43-59)
32.4 (27.9-35.5)
1.69 (1.40-2.48)
1.58 (1.38-1.97)
37 (30.5-42.0)
1.02 (0.95-1.09)
9.5 (7.9-12.0)
73 (68-86)
150 (122-164)
91 (79-100)
1.10 (0.92-1.39)
20 (13-26)
124 (111-143)
70 (63-81)
174 (155-190)
70 (70-80)
24.0 (19.7-29.8)
99 (98-100)
97 (95-99)
1 (0-4)
0.67 (0.54-0.78)
23.0 (12.1-41.5)
47.7 (42.2-53.1)
36 (31-42)
1.26 (1.03-1.62)

Data are listed as median and (interquartile range) or n (%).
Abbreviations: VO2=oxygen consumption; METS=metabolic equivalents; VAT=ventilatory anaerobic
threshold; VE/VCO2=minute ventilation to carbon dioxide production; OUES=oxygen uptake efficiency
slope; OUEP=oxygen uptake efficiency plateau; RER=respiratory exchange ratio; APMHR=age-predicted
maximal heart rate, SPO2=oxygen saturation; VE/MVV=peak minute ventilation/maximal voluntary
ventilation ratio.
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Pulmonary Function Results
The majority of the cohort (n=16 [53%]) did not show evidence of any significant
airflow limitation while the remaining subjects were graded according to GOLD criteria
as follows: Grade 1 (Mild) = 2 (7%); Grade 2 (Moderate) = 7 (23%); Grade 3 (Severe) =
4 (13%); Grade 4 (Very Severe) = 1 (3%). Presence of airflow limitation was not
identified in the breast CA patients and was predominantly confined to those with lung
CA (n=13/14 [93%] of the remaining cohort). Table 8 provides a detailed assessment of
spirometry values for the entire cohort.

Table 8: Pulmonary Function Results of the Cohort.
Variables
Entire Cohort (N=30)
Forced Vital Capacity (Liters)
2.80 (2.39-3.40)
FVC%
83 (74-97)
Forced Expiratory Volume 1-second (Liters)
2.01 (1.50-2.46)
FEV1%
75 (55-95)
FEV1/FVC ratio
0.72 (0.57-0.79)
Forced Expiratory Flow 25-75%
1.33 (0.85-2.26)
FEF%
51 (31-95)
Peak Expiratory Flow (L/Sec)
4.61 (3.29-5.80)
PEF%
67 (46-98)
Direct MVV (Liters per minute)
72.4 (54.2-95.6)
MVV%
78 (45-92)
Data are listed as median and (interquartile range).
Abbreviations: FVC=Forced vital capacity; FEV1=Forced expiratory volume in 1-second;
FEF=Forced expiratory flow; PEF=Peak expiratory flow; MVV=Maximal voluntary
ventilation.

Doppler Echocardiography
Two-dimensional echocardiography revealed half of the subjects (n=15 [50%])
had an LVEF (52 (47-60)%) less than the lower limit of the normal reference range (5373%, mean2-standard deviations [SD]). Using European Society of Cardiology (ESC)
criteria(231): two patients had a reduced LVEF (<40%), seven had a mid-range LVEF
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(≥40% - 49%) with the remaining having LVEF’s ≥50%. Thirteen (43%) patients met
criteria for diastolic dysfunction based upon ESC recommendations defined as at least
two of the following to be present: functional alterations of - E/e’>13; or mean e’ <9
cm/s; or structural alterations of - left-atrial volume index (LAVI) >34 mL/m2; or leftventricular hypertrophy.(231) Furthermore, when using the ESC Diagnostic algorithm
for a diagnosis of heart failure of non-acute onset and assigning exercise
intolerance as a typical symptom of HF with the exposition to cardiotoxic drug/radiation
as an assessment of HF probability the prevalence of HFpEF was 21% in the cohort
evidenced by a NTproBNP ≥125 pg/mL and the aforementioned echo diastolic
dysfunction criteria with a preserved LVEF (≥50%). Table 9 provides a detailed
summary of the Doppler echocardiographic variables of the entire cohort. In univariate
analysis, the echo-derived resting e’ (R=-0.562, P=0.024), and stress echo  VTICO
exercise (R=-0.521,

P=0.046) both correlated with the MCRD.
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Table 9: Echocardio-Doppler Parameters.
Variables
Left-ventricular ejection fraction (%)
LVEDV (mL)
LVESV (mL)
Stroke Volume (mL)
LVEDV Index (mL)
LVESV Index (mL)
Stroke Volume Index (mL/m2)
E (cm/s)
A (cm/s)
E/A ratio
LAVI (mL/m2)
e’ (cm/s)
s’ (cm/s)
a’ (cm/s)
Deceleration time (ms)
E/e’
e’/DT
Exercise E (cm/s)
Exercise e’ (cm/s)
 e’exercise (cm/s)
Exercise E/e’
 E/e’exercise
DFRI (e′rest•Δe′exercise)
LVOT VTI – Rest (cm)
LVOT VTI – Exercise (cm)
 LVOT VTIexercise

Entire Cohort (N=30)
52 (47-60)
83 (70-102)
41 (30-51)
44 (36-52)
45 (39-56)
22 (16-26)
23 (19-29)
74.1 (62.3-87.3)
86.5 (72.5-94.2)
0.89 (0.72-1.03)
21.2 (17.1-28.1)
8.0 (7.1-9.6)
7.9 (7.1-8.7)
10.3 (8.2-11.4)
215 (172-244)
8.9 (7.0-12.8)
0.039 (0.031-0.046)
100 (76-123)
10.7 (7.8-14.9)
1.3 (-0.5-5.3)
7.9 (7.0-13.5)
0.4 (-2.8-1.9)
12.5 (-3.8-48.7)
16.6 (14.4-20.4)
19.5 (17.5-25.0)
3.1 (2.1-5.9)

Data are listed median and (interquartile range).
Abbreviations: LVEDV=left-ventricular end-diastolic volume; LVESV=left-ventricular end-systolic
volume; E=early transmitral velocity; A=late transmitral velocity; LAVI=left-atrial volume index; e’= early
diastolic mitral annular velocity; s’=longitudinal systolic strain; a’=late diastolic myocardial velocity;
E/e’=ratio of early transmitral velocity to early diastolic mitral annular velocity; e’/DT=ratio of early
diastolic mitral annular velocity to deceleration time; DFRI= diastolic functional reserve index;
cm/s=centimeters per second; ms=milliseconds; LVOT VTI=left-ventricular outflow tract velocity time
integral.

Cardiac-specific Blood-based Biomarker Assessment
Table 10 indicates the proportion of the cohort with abnormal responses for each
blood-based biomarker and the median values for each. Elevated hsCRP and
NTproBNP was noted in over half of all subjects. The cardiac troponins hs-cTnI and hs-
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cTnT were detected in 28/30 (93%) and 29/30 (unable to detect hs-cTnT in 1-subject
due to hemolysis) (97%) of all subjects, respectively.

Table 10: Cardiac-specific Blood-based Biomarkers.
Biomarker
Abnormal Response
NTproBNP (pg/mL)
18 (60%)
hsCRP (mg/L)
19 (63%)
Galectin-3 (ng/mL)
10 (33%)
hs-cTnT (ng/L)
5 (17%)
hs-cTnI (ng/L)
3 (10%)

Values
187 (51-310)
2.9 (1.5-6.2)
15.0 (13.3-18.8)
9.05 (5.28-12.79)
3.00 (2.00-6.50)

Legend: Date are listed as n (%) or median and (interquartile range). Abnormal
response was defined as: NTproBNP ≥125 pg/mL, hsCRP >2 mg/L, Galectin-3 >17.8
ng/mL, hs-cTnT >22ng/L-Male and >14ng/L-Female, hs-cTnI >14ng/L-Male and
>11.1ng/L-Female.
Abbreviations: NTproBNP=N-terminal pro-brain natriuretic peptide; pg/mL=picograms per milliliter;
hsCRP=high-sensitivity C-reactive protein; mg/L=milligrams per liter; hs-cTnT=high-sensitivity cardiac
troponin T; ng/L=nanograms per liter; hs-cTnI=high-sensitivity cardiac troponin I; ng/mL=nanograms
per milliliter.

Health-Related Quality of Life and Physical Activity Questionnaires
The median FACT-G7 was within a normal range with a score 20 (15.0-23.5).
FACT-G7 scores did not significantly correlate with peak VO2, echo parameters, cardiac
biomarkers, or CMR variables (all P’s>0.06). The median IPAQ score was 792 (3301689) MET-min/week and the distribution of physical activity (PA) according to IPAQ
categories was as follows: Category-1 (Inactive) = 40%, Category-2 (Minimally Active) =
40%, Category-3 (Highly Activity) = 20%. The IPAQ-derived MET-min/week as a
continuous variable or PA categories did not correlate with peak VO2 (R=0.207,
P=0.282) and (R=0.145, P=0.452), respectively. However, the FACT-G7 score did
demonstrate a significant positive relationship with the IPAQ-derived volume of PA
(R=0.423, P=0.02).
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Cardiac Magnetic Resonance Imaging
Using CMR assessment of LVEF: 8 (27%) had an LVEF below the lower limit of
normal (<57%, mean  2SD) and 2 (7%) had an LVEF greater than the upper limit of
normal (>77%, mean  2SD).(232) The CMR LVEF, ECV, left-ventricular end-diastolic
volume (LVEDV), left-ventricular end-systolic volume (LVESV), SV, SV index (SVI),
LGE, or myocardial T1 mapping (pre- and post-contrast) did not correlate with MCRD
(all R’s<0.31, P’s>0.12) or peak VO2 (all R’s<0.3, P’s>0.08). Table 11 provides a
detailed description of the CMR variables of interest.
Table 11: Cardiac Magnetic Resonance Imaging Parameters.
Variables
Entire Cohort (N=30)
Left-ventricular ejection fraction (%)
64 (53-74)
LVEDV (mL)
117.2 (93.6-136.6)
LVESV (mL)
40.5 (31.1-62.0)
LV Stroke Volume (mL)
68.2 (54.9-80.6)
LV Stroke Volume Index (mL/m2)
38.0 (31.0-43.8)
Presence of late-gadolinium enhancement
12 (41%)
Myocardial T1 Mapping (ms)
1030 (1016-1067)
Post-contrast myocardial T1 Mapping (ms)
442 (416-466)
Extracellular Volume (%)
26.9 (24.8-29.2)
Data are listed as median and (interquartile range) or n (%).
Abbreviations: LVEDV=left-ventricular end-diastolic volume; LVESV=left-ventricular end-systolic
volume; mL=milliliter; mL/m2=milliliters per meter squared; ms=milliseconds.

Limitation to Exercise
Normal aerobic exercise capacity was observed in 8 (27%) subjects evidenced
as a peak VO2 above 83% of predicted per age, sex, height, and weight. In the
remaining 22 (73%) of subjects with a reduced peak VO2 <83% of predicted, 9 (30%)
demonstrated a predominant CV limitation, 8 (27%) a pulmonary limitation, and 5 (17%)
a non-cardiopulmonary or indeterminate limitation to exercise. Table 12 details the
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comparison of groups based upon aerobic exercise capacity and the predominant
limitation to exercise. There were significant differences between the groups in CA type
(x2=[3, n=30] 16.7, P<0.01), peak VO2 (P<0.01), FEV1 (P<0.01), and MCRD (P=0.03).
Between group comparisons using Bonferroni correction of continuous variables
revealed peak VO2 was significantly higher in those with normal exercise capacity
relative to those with a predominant pulmonary limitation (P<0.01) or those with a
predominant cardiac limitation to exercise (P<0.01). The FEV1 was significantly higher
in the normal aerobic exercise capacity group compared to those with a pulmonary
limitation (P<0.01). Furthermore, the MCRD was lower in those with normal aerobic
exercise capacity compared to those with a pulmonary limitation (P=0.05).
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Table 12: Comparison of groups based upon limitation to exercise.
Normal
CV
Pulmonary Indeterminate
Exercise
Limitation Limitation
Limitation
Capacity
(n=9)
(n=8)
(n=5)
(n=8)
Age (years)
59.5
59.0
63.5
64.0
(49.5-67.5) (49.0-65.0) (57.5-72.3)
(61.5)
Female
8 (100%)
4 (44%)
3 (38%)
3 (60%)
Breast CA
7 (88%)
1 (11%)
0 (0%)
2 (40%)
Peak VO2
22.8
16.0
15.5
16.5
(20.5-25.0) (13.7-17.6) (11.7-18.8)
(13.7-18.5)
2
BMI (kg/m )
27.0
25.1
26.3
36.9
(22.9-30.6) (19.7-30.2) (23.6-28.0)
(29.5-46.2)
FEV1 (Liters)
2.35
2.11
1.12
1.90
(2.10-2.72) (1.49-2.53) (0.87-1.86)
(1.74-2.59)
MRI LVEF (%)
65
59
60
73
(63-75)
(53-68)
(46-73)
(54-78)
Chemotherapy
7 (88%)
9 (100%)
5 (63%)
5 (100%)
MCRD (Gy)
3.5
10.3
12.3
10.7
(2.7-5.1)
(4.0-22.6)
(5.2-26.5)
(4.4-20.3)
Time since RT
1.5
1.8
5.2
0.5
(years)
(0.7-2.5)
(0.4-4.0)
(1.7-7.8)
(0.2-2.6)
Hypertension
4 (50%
6 (67%)
3 (38%)
4 (80%)
Dyslipidemia
4 (50%)
5 (56%)
4 (50%)
4 (50%)
Diabetes
3 (38%)
1 (11%)
1 (13%)
3 (38%)
Obesity
3 (38%)
3 (33%)
1 (13%)
3 (60%)
Smoking
0 (0%)
1 (11%)
4 (50%)
1 (20%)
MET-min/week
1689
462
662
2523
(1064-4467) (132-983)
(26-924)
(468-8025)

Pvalue

0.42
0.05
<0.01
<0.01
0.08
<0.01
0.34
0.11
0.03
0.16
0.44
0.42
0.63
0.37
0.08
0.09

Data are listed as median and (interquartile range) or n (%).
Abbreviations: CA=cancer; VO2=oxygen consumption; BMI=body mass index; FEV1=forced expiratory
volume in 1-second; MRI=magnetic resonance imaging; LVEF=left-ventricular ejection fraction;
MCRD=mean cardiac radiation dose; Gy=Gray units; RT=radiotherapy; MET=metabolic equivalent.

Predictors of Peak Oxygen Uptake
An assessment of pre-specified physiologic predictors of peak VO2 listed in
Table 13 at univariate analysis revealed significant associations with RT, cardiac, body
composition, and ventilatory parameters and includes the variables retained in a
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multivariate analysis model. The MCRD demonstrated a significant inverse association
(Figure 2) with peak VO2 (R=-0.380, P=0.04), but total prescribed radiation dose or
MLRD did not reveal a significant relationship.
The cardiac parameters e’, E/e’, E/e’ exercise, e’/DT ratio, DFRI, VTICO exercise,
NTproBNP, hs-cTnI, and hs-cTnT were all significantly associated with peak VO2 in the
entire cohort. The waist/hip ratio was the only body composition parameter that
demonstrated a significant correlation with peak VO2 (R=-0.431, P=0.03). The
ventilatory parameters FVC, FEV1, FEV1/FVC, MVV, and SPO2 with exercise were all
associated with peak VO2 at univariate analysis.
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R=-0.380, P=0.04

Figure 2. Relationship of peak VO2 to the mean cardiac radiation dose.
Abbreviations: VO2=oxygen consumption; MCRD=mean cardiac radiation dose; Gy=Gray units.

87

Pre-specified cardiac, pulmonary, and body composition parameters that
demonstrated a significant relationship to peak VO2 (P<0.05) were entered into a
stepwise multivariate regression model that revealed the DFRI and NTproBNP were
both independent predictors of peak VO2 in the entire cohort (R2=0.73, P<0.01; DFRI ß=0.765, P<0.01; NTproBNP - ß =-0.389, P=0.04).
The DFRI and NTproBNP were then entered into a general linear model with the
addition of two potential categorical predictors: 1) CA-type (breast vs. lung and other
diseases) and 2) use of anthracycline-based chemotherapy (yes or no). This resulted in
the loss of NTproBNP as an independent predictor (P=0.06), but the DFRI remained
strongly associated with peak VO2 (R2=0.74, P<0.01).
The DFRI reflects the velocity of myocardial relaxation at rest and with exercise. The
strong association between DFRI and peak VO 2 supports a central role of impaired left
ventricular diastolic reserve in the pathophysiology of radiation-induced exercise
intolerance.
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Table 13: Multivariate Analysis of Predictors of Peak VO2 for the Entire Cohort.
Variable
R-value Univariate P-value Multivariate P-value
Radiotherapy Parameters
Total Prescribed Dose (Gy)
0.610
0.76
MCRD (Gy)
-0.380
0.04
0.64
MLRD (Gy)
0.123
0.54
Cardiac Parameters
MRI LVEF (%)
0.050
0.80
ECV (%)
-0.177
0.39
Rest e’
0.494
<0.01
0.76
E/e’
-0.552
<0.01
0.31
0.644
<0.01
0.41
 e’exercise
Exercise e’
0.574
0.02
0.58
Exercise E/e’
-0.487
0.08
-0.329
0.21
 E/e’exercise
e’/DT ratio
0.427
0.02
0.58
DFRI
0.693
<0.01
<0.01
Exercise VTICO
0.200
0.46
0.614
0.02
0.86
 VTICO exercise
NTproBNP
-0.590
<0.01
0.04
hs-cTnI
-0.515
<0.01
0.66
hs-cTnT
-0.550
<0.01
0.57
Galectin-3
-0.279
0.14
hsCRP
-0.301
0.11
Body Composition Parameters
Weight (kg)
-0.157
0.42
BMI
-0.051
0.80
Waist Circumference
-0.368
0.06
W/H Ratio
-0.431
0.03
0.82
Fat Mass%
-0.008
0.97
Fat Mass Index
-0.013
0.95
Fat-Free Mass%
-0.005
0.98
Fat-Free Mass Index
-0.186
0.33
Ventilatory Parameters
FVC
0.469
0.01
0.54
FEV1
0.673
<0.01
0.16
FEV1/FVC
0.550
<0.01
0.21
Direct MVV
0.600
<0.01
0.07
-0.429
0.02
0.70
 SPO2 exercise
Abbreviations: Gy=Gray; MCRD=mean cardiac radiation dose; MLRD=mean lung radiation dose;
LVEF=left-ventricular ejection fraction; e’=early diastolic mitral annular velocity; E/e’=ratio of early
transmitral velocity to early diastolic mitral annular velocity; =delta; e’/DT=ratio of early diastolic mitral
annular velocity to deceleration time; DFRI= diastolic functional reserve index; VTICO =left-ventricular
outflow tract velocity time integral cardiac output; NTproBNP=N-terminal pro-brain natriuretic peptide;
hs-cTnT=high-sensitivity cardiac troponin T; hs-cTnI=high-sensitivity cardiac troponin I; hsCRP=highsensitivity C-reactive protein; kg=kilograms; BMI=body mass index; W/H=waist/hip; FVC=Forced vital
capacity; FEV1=Forced expiratory volume in 1-second; MVV=Maximal voluntary ventilation;
SPO2=oxygen saturation.
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Predictors of peak VO2 according to primary cause of limitation.
Dividing the cohort by primary exercise limitation (cardiac vs. pulmonary vs.
other) and examining the predictors of peak VO 2 in each group revealed the relationship
between MCRD and peak VO2 was further strengthened (Figure 3) (R=-0.569, P=0.02)
in those with a primary cardiac limitation to exercise. Doppler-derived stress echo
diastolic parameters (e’ with exercise, exercise e’, DFRI), cardiac-specific biomarkers
(NTproBNP, hs-cTnT), and pulmonary function (FEV1, MVV) were also univariate
predictors of peak VO2 (Table 14). None of the body composition parameters correlated
with peak VO2 in those with a cardiac limitation to exercise. A multivariate stepwise
regression model created using significant univariate predictors (P<0.05) revealed that
the variable: exercise e’ was an independent predictor of peak VO2 (R=0.785, P=0.01).
Exercise e’ reflects the velocity of myocardial relaxation with exercise. Also, in this
subgroup, the strong association between diastolic reserve and peak VO 2 support its central
role of in the pathophysiology of radiation-induced exercise intolerance.

Those limited predominantly by a pulmonary limitation to exercise also
demonstrated significant associations between peak VO2 and Doppler-derived
rest/stress echo diastolic parameters (e’, E/e’, e’ exercise, exercise e’, exercise E/e’,
E/e’ exercise, DFRI, exercise VTICO,  VTICO exercise), cardiac-specific biomarkers (hs-cTnI,
Gal-3), and pulmonary function (MVV, SPO2exercise) parameters (Table 15). None of
the body composition parameters correlated with peak VO2 in those with a primary
pulmonary limitation to exercise. In a multivariate model, only the echo-Doppler diastolic
parameter, exercise E/e’ reflective of the increase in LV filling pressure with exercise was
an independent predictor of peak VO2 (R=1.00, P<0.001). Also, in this subgroup with
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pulmonary limitation, the strong inverse association between diastolic function and peak
VO2 support its central role of in the pathophysiology of radiation-induced exercise
intolerance.

In those with an indeterminate or non-cardiopulmonary limitation to exercise only
the Doppler-derived echo diastolic parameter: resting E/e’ and hsCRP were univariately
associated with peak VO2. However, due to the small size of the sample (n=5)
multivariate analysis was not performed.

91

R=-0.569, P=0.02

Figure 3. Relationship of peak VO2 to the mean cardiac radiation dose in individuals
with a predominant cardiac limitation to exercise.
Abbreviations: VO2=oxygen consumption; MCRD=mean cardiac radiation dose; Gy=Gray units.
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Exploratory Analysis: Relationship of Other CPET Variables to Mean Cardiac
Radiation Dose.

In addition to peak VO2, numerous other CPET-derived variables correlated with
radiation doses.
Peak VO2 in absolute values (mL·min-1) moderately correlated with MCRD (R=0.432, P=0.019), V5Gy (R=-0.434, P=0.019), and V10Gy (R=-0.470, P=0.010). Percentpredicted peak VO2 demonstrated a significant inverse relationship with MCRD (R=0.471, P=0.010), V5Gy (R=-0.453, P=0.014), V10Gy (R=-0.489, P=0.007), V20Gy (R=0.413, P=0.026, and V40Gy (R=-0.369, P=0.045).
The peak %-predicted O2 pulse was inversely associated with all RT doses:
MCRD (R=-0.505, P=0.005), V5Gy (R=-0.514, P=0.004), V10Gy (R=-0.561, P=0.002),
V20Gy (R=-0.452, P=0.014), V30Gy (R=-0.476, P=0.009), V40Gy (R=-0.536, P=0.003),
and V50Gy (R=-0.420, P=0.023).
The OUEP and %-predicted OUEP also demonstrated significant inverse
associations with MCRD ([R=-0.419, P=0.024], V5Gy [R=-0.463, P=0.012], V10Gy [R=0.465, P=0.011] and %-predicted OUEP: MCRD [R=-0.429, P=0.020], V5Gy [R=-0.477,
P=0.009], V10Gy [R=-0.466, P=0.011]), respectively.
The standard exercise test variables maximal HR and the rate-pressure product
(RPP) (Max HR x Max systolic BP) inversely correlated with MCRD ([R=-0.441,
P=0.017], [R=-0.486, P=0.008], V5Gy [R=-0.451, P=0.014], [R=-0.420, P=0.023], and
V10Gy [R=-0.500, P=0.006], [R=-0.467, P=-0.011]), RPP only: V30Gy [R=-0.377
P=0.044], V40Gy [R=-0.394, P=0.035, V50Gy [R=-0.515, P=0.004),respectively.
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Collectively, including peak VO2, the %-predicted peak O2 pulse showed the
strongest correlations with MCRD and %heart volume exposed to RT dose.
Interestingly, other key CPET variables(167) including the VE/VCO2 slope (R=0.259,
P=0.175), exercise time (R=-0.352, P=0.061), HRR-1’ (R=-0.127, P=0.513), and the
OUES (R=0.048, P=0.807) did not correlate with MCRD.
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Table 14: Multivariate Analysis by Cardiac Limitation to Exercise.
Variable
R-Value Univariate P-value Multivariate P-value
Radiotherapy Parameters
Total Prescribed Dose (Gy)
0.209
0.42
MCRD (Gy)
-0.569
0.02
MLRD (Gy)
0.017
0.95
Cardiac Parameters
MRI LVEF (%)
0.049
0.85
ECV (%)
-0.129
0.65
Rest e’
0.407
0.13
E/e’
-0.482
0.06
0.700
0.04
 e’exercise
Exercise e’
0.693
0.03
0.01
Exercise E/e’
-0.576
0.08
-0.139
0.70
 E/e’exercise
e’/DT ratio
0.344
0.19
DFRI
0.783
0.01
Exercise VTICO
0.103
0.78
0.633
0.07
 VTICO exercise
NTproBNP
-0.601
0.01
hs-cTnI
-0.309
0.23
hs-cTnT
-0.598
0.01
Galectin-3
0.174
0.50
hsCRP
-0.243
0.35
Body Composition Parameters
Weight (kg)
-0.135
0.61
BMI
-0.059
0.82
Waist Circumference
-0.374
0.17
W/H Ratio
-0.364
0.18
Fat Mass%
-0.022
0.93
Fat Mass Index
-0.056
0.83
Fat Free Mass%
0.054
0.84
Fat Free Mass Index
-0.199
0.45
Ventilatory Parameters
FVC
0.401
0.11
FEV1
0.628
<0.01
FEV1/FVC Ratio
0.400
0.11
Direct MVV
0.488
<0.05
-0.230
0.37
 SPO2exercise
All abbreviations are the same as Table 13.

95

Table 15: Multivariate Analysis by Pulmonary Limitation to Exercise.
Variable
R-Value Univariate P-value Multivariate P-value
Radiotherapy Parameters
Total Prescribed Dose (Gy)
0.000
1.00
MCRD (Gy)
0.357
0.39
MLRD (Gy)
0.638
0.17
Cardiac Parameters
MRI LVEF (%)
-0.321
0.48
ECV (%)
0.143
0.76
Rest e’
0.714
<0.05
E/e’
-0.762
0.03
1.000
<0.01
 e’exercise
Exercise e’
1.000
<0.01
Exercise E/e’
-1.000
<0.01
<0.001
-1.000
<0.01
 E/e’exercise
e’/DT ratio
0.381
0.35
DFRI
1.000
<0.01
Exercise VTICO
-1.000
<0.01
1.000
<0.01
 VTICO exercise
NTproBNP
-0.476
0.23
hs-cTnI
-0.719
<0.05
hs-cTnT
-0.381
0.35
Galectin-3
-0.833
0.01
hsCRP
-0.381
0.35
Body Composition Parameters
Weight (kg)
0.143
0.74
BMI
0.143
0.74
Waist Circumference
-0.238
0.57
W/H Ratio
-0.143
0.74
Fat Mass%
-0.190
0.65
Fat Mass Index
-0.190
0.65
Fat Free Mass%
0.190
0.65
Fat Free Mass Index
0.167
0.69
Ventilatory Parameters
FVC
0.548
0.16
FEV1
0.595
0.12
FEV1/FVC Ratio
0.690
0.06
Direct MVV
0.762
0.03
-0.741
0.04
 SPO2exercise
All abbreviations are the same as Table 13.
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DISCUSSION
The results of this pilot study indicate aerobic exercise capacity defined as peak
VO2 is markedly reduced (38% less than predicted normal values) in CA patients who
have previously undergone thoracic radiation wherein the heart received significant RT
dose. This exercise intolerance is multifactorial but our results indicate this is
predominantly due to a cardiac dysfunction in a group of patients without a clinical
diagnosis of CVD. The Doppler-stress echo-derived diastolic functional reserve index
(DFRI) and the cardiac-biomarker NTproBNP are strong, independent predictors of
peak VO2. Reduced aerobic exercise capacity is inversely associated with multiple
indices of abnormal CV function using multiple imaging and biomarker analyses.
Furthermore, the MCRD received during RT correlates with aerobic exercise capacity.
This indicates CRF is sensitive to detect latent CV abnormalities in this cohort. This
confirms the presence of impaired CRF in patients with CA who have previously
undergone thoracic radiation wherein the heart received significant RT dose. The
results also further show that the impairment in CRF shows a dose-dependent
relationship with the radiation dose to the heart, and that impaired CRF is predominantly
due to cardiovascular limitations in diastolic function with exercise (impaired diastolic
reserve).

Aerobic exercise capacity is reduced in CA survivors whom have previously
undergone thoracic radiation wherein the heart received significant RT dose.
The results of the current study demonstrate aerobic exercise capacity is
markedly reduced in CA patients who have previously undergone thoracic radiation

97

wherein the heart received significant RT dose. Exercise capacity in this population has
not been previously been characterized to this detail in reference to the RT regimen.
The finding of reduced exercise capacity has been previously observed by others in the
study of CA survivors who have anti-CA therapies.(166, 170, 174, 233, 234) Jones et al.
evaluated peak VO2 in 47 post-menopausal hormone receptor+ breast CA women who
all received anthracycline-based chemotherapy and 98% also underwent RT
(mean=47±2.4 Gy) and observed a peak VO2 of 17.9±4.3 mL·kg-1·min-1 or 24% below
age-gender matched healthy controls. Significant univariate predictors of peak VO2
were BMI, glucose, CRP, and insulin. Associations with RT dose and/or MCRD was not
reported.(233)
In yet another study Jones et al. evaluated the CV risk profile including CRF in 26
early-stage HER2+ breast CA patients (65% received RT) treated with adjuvant taxaneanthracycline chemotherapy and/or trastuzumab.(174) Peak VO2 was 19.2
mL·kg-1·min-1 and was significantly lower than controls. However, radiotherapy dose
and/or MCRD was not reported.
Burnett and colleagues sought to determine the proportion of breast CA survivors
(at least 3-months post-chemotherapy or left-chest RT, 80% received anthracyclinebased chemotherapy, 40% received RT) with 2 or more CVD risk factors exhibiting a
low VO2 max in 30 patients.(166) The mean VO2 was 25.4±5.3 mL·kg-1·min-1 which was
commensurate to the 20th percentile threshold value for age-gender matched normative
values with 77% having values below the 20th percentile value. Radiotherapy dose
and/or MCRD was not reported.
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A study by Adams et al. looked at CV status in 48 Hodgkin’s disease survivors
who received mediastinal irradiation (40 [27.0-51.7] Gy).(234) The peak VO2 was
significantly reduced (defined as < 20 mL·kg-1·min-1) in 30% of survivors. Furthermore,
VO2 max was significantly correlated with increasing fatigue, shortness of breath, and
decreased physical component scores on the short-form-36 HRQOL questionnaire. All
subjects in this study underwent mediastinal RT, but relationships with dose and/or
heart involvement was not reported.
A review by Peel and colleagues developed normative values for peak VO2 in
breast CA patients.(170) They identified 27 clinical trials involving a total of 1,856
females (chemotherapy: n=78%, RT=56%, endocrine therapy= 33%) directly measuring
pVO2 in the pre- or post-adjuvant setting. Radiotherapy dose and/or MCRD was not
reported. The mean pVO2 prior to adjuvant therapy was 24.6 ml•kg-1•min-1, whereas the
mean pVO2 post-adjuvant therapy was 22.2 ml•kg-1•min-1. This equated to a postadjuvant reduction in VO2 of -2.4 ml•kg-1•min-1or 10% lower. Compared with reference
values the pre-adjuvant VO2 values were significantly lower (17%) than that of healthy,
sedentary women (29.7 ml•kg-1•min-1) or 83% of predicted . In the post-adjuvant setting,
pVO2 was 25% lower (75% of predicted) compared to healthy, sedentary values.
A summarization of these prior studies in CA survivors is that reduced CRF is
consistently observed in CA patients compared with normative values. Exercise testing
occurred at different time points across the CA treatment continuum and has largely
been cross-sectional in nature. They were treated predominantly with chemotherapy
although a majority also having received adjuvant RT. The reduction in CRF appears to
be more pronounced in the post-adjuvant period and is associated with a higher
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prevalence of CVD risk factors. Reduced CRF is usually observed in the setting of a
normal LVEF. The novelty of the current study lies in its detailed characterization of the
exercise response in CA survivors and the contribution of significant RT dose to the
heart.

CRF in RT-treated chest CA survivors with significant heart dose is influenced
predominantly due to cardiovascular dysfunction.
Cardiorespiratory fitness is determined by the components of the Fick equation
where: VO2 = CO x a-vO2 difference. In normal healthy individuals and patients with
systolic HF, CO is generally regarded as the primary determinant of CRF although this
has not been consistently shown in those with HFpEF, the predominant HF phenotype
in the breast CA patient.(235–237)
In the aforementioned study by Jones et al. the decreased peak VO2 in breast
CA patients with a preserved LVEF (>50%) using impedance cardiography was due to a
reduced CO response attributed to a blunted increase in SV with exercise compared
with controls.(233) This was based on the finding that peak HR and a-vO2 difference
was not different between the groups. The finding of a similar a-vO2 difference,
however, may suggest impaired microvascular dysfunction and/or skeletal muscle
abnormalities may also limit peak VO2 as oxygen extraction is directly proportional to
muscle oxygen diffusion conductance and inversely related to CO.(238, 239)
Khouri et al. evaluated peak VO2, LV volumes, and CO using stress 2DE in 57
female breast CA patients treated with doxorubicin-containing adjuvant therapy (79%
received RT).(161) Peak VO2 was 20% lower in patients and stress echo SV and
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cardiac index (CI) were lower than controls. Furthermore, the post-stress increase in CI
predicted peak VO2.
A study by Koelwyn et al. evaluated arterial elastance (Ea), end-systolic
elastance (Ees), and ventricular-arterial coupling (Ea/Ees) to determine the presence of
vascular dysfunction following anthracycline-based chemotherapy.(175) In a crosssectional design, 30 ER+, HER2- breast CA survivors (77% underwent RT) and 30 ageBMI-activity-matched controls underwent discontinuous CPET on an upright bicycle
ergometer with 2DE images obtained at 25%, 50%, and 75% of peak work rate to
calculate EDV, ESV, and LVEF. Central and peripheral vascular structure and function
was also assessed. No significant differences were noted with resting measures of
ventricular-arterial coupling between groups. The exercise Ea response was also not
significantly different in survivors compared with controls. However, Ees was
significantly reduced in survivors during exercise with a resulting elevated Ea/Ees ratio
compared with controls at all exercise stages. Resting measures of LV systolic function
were not different between CA survivors and controls, but LVEF was reduced at all
three submaximal workloads in the survivor group. No significant differences between
groups were found in regards to central and peripheral vascular structure and function.
The results of this study indicate impaired ventricular-arterial coupling due to a reduced
LV contractility in breast CA survivors at a mid-term follow-up period (>5-years) who
were previously treated with anthracyclines with a majority having underwent adjuvant
RT.
Conversely, in a small pilot feasibility study (n=14) of comprehensive pulmonary
evaluation following thoracic lung RT in childhood CA survivors, De and colleagues
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described the prevalence of CPET abnormalities.(240) In 14 subjects (median time
since RT=4.8 years, prescribed RT dose=21 Gy, MLRD=11.9 Gy), of which 11
underwent CPET where nine patients demonstrated CPET abnormalities with the
majority, seven (64%) being described as having a pulmonary limitation to exercise.
However, they did not report CRF metrics, MCRD, or the status of CV function.
These studies allude to seemingly normal cardiac function in CA patients who
have undergone anti-CA treatments when referencing resting values but reveal
unmasking of cardiac abnormalities when subjected to stress. The majority of studies
examining exercise determinants in CA survivors to date have been cardio-centric with
most of the emphasis being placed on indices of systolic function.(161, 174, 175)
Presently, there is scant information on the contribution of diastolic dysfunction on CRF
in CA survivors although breast CA survivors share a number of risk factors associated
with HFpEF patients.(66, 104) Heart failure with a preserved ejection fraction is a
heterogeneous syndrome although evidence of diastolic dysfunction is a critical
component.(231)
In an elegant animal model, Saiki et al. used cardiac radiation exposure to induce
diastolic dysfunction with preserved ejection fraction.(241) Male rats were subjected to
diffuse cardiac radiation at two different doses (10 and 20 Gy) using adeno-associated
virus serotype-9 gene delivery of the rat sodium-iodide symporter gene followed by
injection of radioactive Iodine-131 at 10-weeks age, were followed for five-months, and
then underwent treadmill exercise testing, echo, hemodynamic catheterization, and
tissue harvest. Radiation treated rats had reduced exercise capacity, increased LV
diastolic stiffness, impaired myocardial relaxation, elevated filling-pressures, but similar
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LVEF compared with controls. Post-hoc analysis showed evidence of a significant
inverse linear trend between exercise capacity and radiation dose suggesting a doseresponse relationship. Exercise capacity was inversely correlated with mean circulatory
filling pressure, positively correlated with microvascular density, and inversely correlated
with LV fibrosis. Pathology revealed increased LV fibrosis, mild concentric
cardiomyocyte hypertrophy, and reduced microvascular density. This study provides
mechanistic insight into pathological link between HFpEF with diastolic dysfunction, RT
exposure, and the resulting impairment of exercise capacity.

Cardiac-biomarker NTproBNP and the diastolic functional reserve index (DFRI)
are strong, independent determinants of peak VO2.
Natriuretic peptides (BNP, NTproBNP) are markers of ventricular wall stress and
are produced endogenously to counteract the adverse effects of sympathetic nervous
system RAAS activation in the presence of cardiac dysfunction.(242) Furthermore,
natriuretic peptides are accurate in the diagnosis of HF, improve risk stratification of HF
patients, improve patient management, may be helpful to screen for asymptomatic LV
dysfunction in high-risk patients, and powerful predictors of outcome in predicting death
and hospitalization in HF patients.(243, 244) The inactive amino-terminal portion of proBNP, NTproBNP, is secreted in equivalent proportions to BNP, but has a longer half-life
and may be more sensitive to detect early stage LV dysfunction.(245) Natriuretic
peptides also inversely correlate with peak VO2 and are sensitive to change with
interventions designed to improve CRF .(246–248) This supports the current study
wherein NTproBNP was a strong, independent predictor of exercise capacity along with
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indices of cardiac dysfunction in chest CA patients who had previously undergone RT
with significant heart dose.
The DFRI has previously been shown to predict exercise capacity in individuals
with exertional diastolic dysfunction with a decreased DFRI indicating exercise
intolerance.(213, 214, 249) The utility of the DFRI is its ability to identify diastolic
abnormalities not apparent at rest. The DFRI is the Doppler-echo derived product of
e′rest•Δe′exercise. The early mitral annulus diastolic velocity (e’), a surrogate of myocardial
relaxation, demonstrates a strong inverse correlation with the isovolumetric time
constant (tau) a reference marker of LV relaxation and is less dependent upon
preload.(250, 251) During exercise, augmentation of CO is achieved by increases in SV
and HR. The tachycardia induced by exercise reduces diastolic filling time and the mitral
inflow rate must increase to maintain or increase SV which can be accomplished by
faster relaxation.(252) However, with diastolic dysfunction augmentation of relaxation is
prevented as the HR increases during exercise.(253) The finding of reduced CRF and
its strong association with DFRI in the present indicates impaired relaxation is driving
the exercise intolerance.

Mean cardiac radiation dose is inversely associated with CRF.
In the current study multiple imaging modalities and cardiac-biomarkers were
utilized with the intent to identify CV abnormalities related to RT dose. Using CMR
techniques (LVEF, LGE, ECV), Doppler echocardiography (systolic and diastolic
parameters, Doppler spectra), and cardiac-specific blood-based biomarkers only the
echo-derived early diastolic mitral annular velocity (e’), and  VTICO exercise were able to
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demonstrate a significant relationship with the MCRD. On the contrary, multiple CRF
variable demonstrated a significant relationship with RT doses. Moreover, this
relationship was further strengthened when evaluating RT dose in those with a
predominant cardiac limitation to exercise. Although a univariate predictor of peak VO2
the MCRD was not an independent predictor in multivariate analysis. This indicates
MCRD is not directly influencing CRF rather the pathophysiology associated with
radiation exposure causes impaired relaxation evidenced by the reduced DFRI leads to
exercise intolerance.
In a population-based case-control study of incident HF in female breast CA
patients (MCRD=2.5 Gy, mean time post-RT=5.8 years), Saiki and colleagues
demonstrated a dose-response relationship between MCRD and the incidence of
HF.(104) The odds ratio (95%CI) for HF per log MCRD was 9.1 (3.4–24.4) for any HF,
16.9 (3.9–73.7) for HFpEF, and 3.17 (0.8–13.0) for HFrEF.
In the Saiki et al. animal study, tau was linearly related to radiation dose.(241)
Rats exposed to 10 Gy demonstrated longer relaxation times compared with controls
and rats receiving 20 Gy had even longer relaxation times.
In another animal study by Mezzarroma et al., contractile reserve measured with
an isoproteronol challenge decreased in a dose-dependent manner.(254) Mice exposed
to two different doses (20 or 14 Gy) experienced a graduated attenuation of %LVEF
change in the acute (72-hours) and late (4-months) stages compared to sham controls.
Wang and colleagues demonstrated a linear relationship between MCRD and the
risk of cardiac events in lung CA patients who had undergone thoracic RT.(255) In 127
patients with stage III NSCLC (ECOG status 0-1, prescribed RT dose=74 Gy,
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MCRD=12.3 Gy, cardiac V5Gy = 36.5%) heart dose and baseline CVD each
independently predicted the incidence of cardiac events.

CRF is sensitive to detect subclinical cardiac dysfunction in CA survivors who
have received thoracic radiation with heart involvement.
Traditionally, cardiotoxicity of anti-CA treatments has been defined by reductions
in the LVEF. The change in LVEF, however, is insensitive to detect subtle declines in
CV function and when it declines may manifest in overt HF with disabling symptoms and
a poor prognosis.(256, 257) This has led to the active investigation of alternative
imaging and blood biomarkers for the detection of early-onset cardiac injury including
cardiac troponins, NTproBNP, echo tissue Doppler imaging, and CMR with LGE
measurements.(258) Although not yet systematically evaluated to detect cardiotoxicity
there have been increasing calls to recognize CPET and the measurement of peak VO2
as a potential diagnostic tool and/or indicator of anti-CA related cardiac
dysfunction.(258, 259) In the present study, peak VO2 demonstrated a dose-response
relationship with RT dose that was strengthened in those with a predominant cardiac
limitation to exercise. Peak VO2, a well-established indicator of prognosis in the cardiac
patient(167), demonstrated strong correlations with NTproBNP, hs-cTnI, hs-cTnT, and
multiple indices of diastolic function which are themselves known to predict
prognosis.(244, 260)

Is CRF a Therapeutic Target to Prevent or Reverse Cardiovascular
Morbidity/Mortality in CA Survivors?
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Cardiorespiratory fitness is a global assessment of the interconnected responses
involving the cardiovascular, pulmonary, skeletal muscle, hematopoietic, and
neuropsychological systems to exercise.(186) The direct and indirect effects of anti-CA
therapies have the potential to adversely influence all of these systems thus reducing
CRF. Exercise training regimens have consistently been shown to have favorable
effects on each of these integrated systems.(261) Furthermore, it has been
demonstrated to be one of the few effective interventions to improve CRF in HFpEF
patients which appears to be the predominant cardiac phenotype in CA patients.(104,
238, 262) An elegant review by Scott et al. recently addressed the efficacy of exercise
on cardiovascular toxicity in adult CA survivors.(263) The results indicate that at present
the results of exercise training to mitigate cardiotoxicity are encouraging, but limited with
most of the evidence coming from observational studies.
Neurohormonal blockade through the use of beta-blockers and RAAS inhibitors
have been shown to decrease cardiac troponin and NTproBNP levels.(264) Evidence is
accumulating for the use of beta-blockers (ß-blockers) in the prevention of
cardiotoxicity.(265) Beta-blocker usage is associated with a lower incidence of HF
following anti-CA treatment with anthracyclines and trastuzumab.(266) Animal studies
allude to the cardio-protective effects of angiotensin-converting enzyme inhibitors (ACEI) in anthracycline cardiotoxicity.(267) In an epidemiological cohort study of 142,990
women with breast CA exposure to ß-blockers and ACE-I (defined as a filled
prescription for such) resulted in a reduction of cardiotoxicity (adjusted hazard ratio
(adj.HR) =0.77 (0.62-0.95) and all-cause mortality (adj.HR=0.79 [0.70-0.90]) compared
with the non-exposed (never prescribed ß-blockers/ACE-I) group.(268) Angiotensin-
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converting enzyme inhibitors also reduce the effects of radiation-induced
nephropathy(269) although the benefit in RIHD has not been demonstrated. The
independent predictive value of NTproBNP on peak VO2 in the current study suggests
this may be viable target to improve cardiorespiratory fitness.
Future Directions
The observational nature of this study cannot prove a cause-effect relationship
between RT dose to the heart and CRF. The demonstration of a direct cause-effect
relationship would require a longitudinal study involving assessment of CRF and cardiac
function both before and after administration of anti-CA therapies. Furthermore, a
prospective interventional study would be required to ascertain if improvements in CRF
translate into improvement of cardiac function and thus reduced CV risk status in this
cohort.
Limitations
The primary limitation of this study is its observational single-time point and thus
leading to a cross-sectional assessment rather than longitudinal assessment of the
disease. Therefore, despite the multiple correlations between cardiac variables, CRF,
and RT dose a cause-effect link cannot be proven.
There was significant heterogeneity in CA type and concomitant anti-CA
systemic agent utilization investigated with this study. However, the unifying
coexistence of a significant cardiac radiation dose threshold, but varying dose amounts
based upon CA type and guideline-directed treatments (i.e. lower in breast CA vs.
higher in lung CA) may have allowed detection of the observed dose-response
relationship.
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From a technical standpoint, when ascertaining organ-system limitation to
exercise, no specific procedures were performed that directly measured peripheral
vascular function or skeletal muscle characteristics both of which are known to
contribute to exercise capacity.(270) There is also the potential confounding effects of
patient medication use on the exercise response observed in this study.

CONCLUSIONS
Impaired CRF is common in patients with CA who have previously undergone
thoracic radiation wherein the heart received significant RT dose. The impairment in
CRF shows a dose-dependent relationship with the radiation dose to the heart, and that
impaired CRF is predominantly due to cardiovascular limitations in diastolic function
with exercise (impaired diastolic reserve). Cardiopulmonary exercise testing is able to
detect subclinical cardiotoxicity in chest CA patients treated with thoracic irradiation
including a significant heart dose. This study warrants further investigation into
radiation-induced exercise intolerance and the efficacy of interventions to improve CRF
in this population.
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